The role of peroxiredoxins in cancer

Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H O , organic hydroperoxides and peroxynitrite. They are highly involved in the control of various physiological functions, including cell growth, differenti...

Full description

Saved in:
Bibliographic Details
Published inMolecular and clinical oncology Vol. 6; no. 2; pp. 139 - 153
Main Authors Nicolussi, Arianna, D'Inzeo, Sonia, Capalbo, Carlo, Giannini, Giuseppe, Coppa, Anna
Format Journal Article
LanguageEnglish
Published England Spandidos Publications 01.02.2017
Spandidos Publications UK Ltd
D.A. Spandidos
Subjects
Antioxidants
Apoptosis
Bladder cancer
Breast cancer
Cancer
Care and treatment
Drug resistance
Enzymes
Esophageal cancer
Free radicals
Liver cancer
Lung cancer
Lymphoma
Mammals
Mesothelioma
Metabolites
Oncology
Organisms
Ovarian cancer
Oxidative stress
Pancreatic cancer
Peroxides
Phylogenetics
Prostate cancer
Reactive oxygen species
Review
Signal transduction
Thyroid gland
Tumors
chemosensitization
chemoresistance
tumorigenesis
peroxiredoxins
oxidative stress
Online AccessGet full text
ISSN2049-9450
2049-9469
DOI10.3892/mco.2017.1129

Cover

Abstract Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H O , organic hydroperoxides and peroxynitrite. They are highly involved in the control of various physiological functions, including cell growth, differentiation, apoptosis, embryonic development, lipid metabolism, the immune response, as well as cellular homeostasis. Although the protective role of PRDXs in cardiovascular and neurological diseases is well established, their role in cancer remains controversial. Increasing evidence suggests the involvement of PRDXs in carcinogenesis and in the development of drug resistance. Numerous types of cancer cells, in fact, are characterized by an increase in reactive oxygen species (ROS) production, and often exhibit an altered redox environment compared with normal cells. The present review focuses on the complex association between oxidant balance and cancer, and it provides a brief account of the involvement of PRDXs in tumorigenesis and in the development of chemoresistance.
AbstractList Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H2O2, organic hydroperoxides and peroxynitrite. They are highly involved in the control of various physiological functions, including cell growth, differentiation, apoptosis, embryonic development, lipid metabolism, the immune response, as well as cellular homeostasis. Although the protective role of PRDXs in cardiovascular and neurological diseases is well established, their role in cancer remains controversial. Increasing evidence suggests the involvement of PRDXs in carcinogenesis and in the development of drug resistance. Numerous types of cancer cells, in fact, are characterized by an increase in reactive oxygen species (ROS) production, and often exhibit an altered redox environment compared with normal cells. The present review focuses on the complex association between oxidant balance and cancer, and it provides a brief account of the involvement of PRDXs in tumorigenesis and in the development of chemoresistance.Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H2O2, organic hydroperoxides and peroxynitrite. They are highly involved in the control of various physiological functions, including cell growth, differentiation, apoptosis, embryonic development, lipid metabolism, the immune response, as well as cellular homeostasis. Although the protective role of PRDXs in cardiovascular and neurological diseases is well established, their role in cancer remains controversial. Increasing evidence suggests the involvement of PRDXs in carcinogenesis and in the development of drug resistance. Numerous types of cancer cells, in fact, are characterized by an increase in reactive oxygen species (ROS) production, and often exhibit an altered redox environment compared with normal cells. The present review focuses on the complex association between oxidant balance and cancer, and it provides a brief account of the involvement of PRDXs in tumorigenesis and in the development of chemoresistance.
Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 KDa) non-seleno peroxidases that catalyze the peroxide reduction of [H.sub.2][O.sub.2], organic hydroperoxides and peroxynitrite. They are highly involved in the control of various physiological functions, including cell growth, differentiation, apoptosis, embryonic development, lipid metabolism, the immune response, as well as cellular homeostasis. Although the protective role of PRDXs in cardiovascular and neurological diseases is well established, their role in cancer remains controversial. Increasing evidence suggests the involvement of PRDXs in carcinogenesis and in the development of drug resistance. Numerous types of cancer cells, in fact, are characterized by an increase in reactive oxygen species (ROS) production, and often exhibit an altered redox environment compared with normal cells. The present review focuses on the complex association between oxidant balance and cancer, and it provides a brief account of the involvement of PRDXs in tumorigenesis and in the development of chemoresistance. Key words: peroxiredoxins, oxidative stress, tumorigenesis, chemoresistance, chemosensitization
Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22–27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H2O2, organic hydroperoxides and peroxynitrite. They are highly involved in the control of various physiological functions, including cell growth, differentiation, apoptosis, embryonic development, lipid metabolism, the immune response, as well as cellular homeostasis. Although the protective role of PRDXs in cardiovascular and neurological diseases is well established, their role in cancer remains controversial. Increasing evidence suggests the involvement of PRDXs in carcinogenesis and in the development of drug resistance. Numerous types of cancer cells, in fact, are characterized by an increase in reactive oxygen species (ROS) production, and often exhibit an altered redox environment compared with normal cells. The present review focuses on the complex association between oxidant balance and cancer, and it provides a brief account of the involvement of PRDXs in tumorigenesis and in the development of chemoresistance.
Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22–27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H 2 O 2 , organic hydroperoxides and peroxynitrite. They are highly involved in the control of various physiological functions, including cell growth, differentiation, apoptosis, embryonic development, lipid metabolism, the immune response, as well as cellular homeostasis. Although the protective role of PRDXs in cardiovascular and neurological diseases is well established, their role in cancer remains controversial. Increasing evidence suggests the involvement of PRDXs in carcinogenesis and in the development of drug resistance. Numerous types of cancer cells, in fact, are characterized by an increase in reactive oxygen species (ROS) production, and often exhibit an altered redox environment compared with normal cells. The present review focuses on the complex association between oxidant balance and cancer, and it provides a brief account of the involvement of PRDXs in tumorigenesis and in the development of chemoresistance.
Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 KDa) non-seleno peroxidases that catalyze the peroxide reduction of [H.sub.2][O.sub.2], organic hydroperoxides and peroxynitrite. They are highly involved in the control of various physiological functions, including cell growth, differentiation, apoptosis, embryonic development, lipid metabolism, the immune response, as well as cellular homeostasis. Although the protective role of PRDXs in cardiovascular and neurological diseases is well established, their role in cancer remains controversial. Increasing evidence suggests the involvement of PRDXs in carcinogenesis and in the development of drug resistance. Numerous types of cancer cells, in fact, are characterized by an increase in reactive oxygen species (ROS) production, and often exhibit an altered redox environment compared with normal cells. The present review focuses on the complex association between oxidant balance and cancer, and it provides a brief account of the involvement of PRDXs in tumorigenesis and in the development of chemoresistance.
Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H O , organic hydroperoxides and peroxynitrite. They are highly involved in the control of various physiological functions, including cell growth, differentiation, apoptosis, embryonic development, lipid metabolism, the immune response, as well as cellular homeostasis. Although the protective role of PRDXs in cardiovascular and neurological diseases is well established, their role in cancer remains controversial. Increasing evidence suggests the involvement of PRDXs in carcinogenesis and in the development of drug resistance. Numerous types of cancer cells, in fact, are characterized by an increase in reactive oxygen species (ROS) production, and often exhibit an altered redox environment compared with normal cells. The present review focuses on the complex association between oxidant balance and cancer, and it provides a brief account of the involvement of PRDXs in tumorigenesis and in the development of chemoresistance.
Audience Academic
Author Nicolussi, Arianna
Coppa, Anna
D'Inzeo, Sonia
Capalbo, Carlo
Giannini, Giuseppe
AuthorAffiliation 2 Department of Molecular Medicine, Sapienza University of Rome, I-00161 Rome, Italy
1 Department of Experimental Medicine, Sapienza University of Rome, I-00161 Rome, Italy
AuthorAffiliation_xml – name: 1 Department of Experimental Medicine, Sapienza University of Rome, I-00161 Rome, Italy
– name: 2 Department of Molecular Medicine, Sapienza University of Rome, I-00161 Rome, Italy
Author_xml – sequence: 1
  givenname: Arianna
  surname: Nicolussi
  fullname: Nicolussi, Arianna
– sequence: 2
  givenname: Sonia
  surname: D'Inzeo
  fullname: D'Inzeo, Sonia
– sequence: 3
  givenname: Carlo
  surname: Capalbo
  fullname: Capalbo, Carlo
– sequence: 4
  givenname: Giuseppe
  surname: Giannini
  fullname: Giannini, Giuseppe
– sequence: 5
  givenname: Anna
  surname: Coppa
  fullname: Coppa, Anna
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28357082$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1PHSEUxUljU626dGsmqYtu5pWvgWFjYoy2TUy60TVh4KKYGXjCvKb978uofa2mhQQI_O65OZz3aCemCAgdEbxivaKfJptWFBO5IoSqN2iPYq5axYXa2Z47vIsOS7nHdSiJaafeoV3as07inu6hk-s7aHIaoUm-WUNOP0IGV9dYmhAba6KFfIDeejMWOHze99HN5cX1-Zf26tvnr-dnV63lhM4t845jSpUEgTvjBy44kM4J4QUTDobOOmfY4BgI4tngvaMDSNIzoEYaYGwfnT7prjfDBM5CnLMZ9TqHyeSfOpmgX77EcKdv03fdsY5IQarAx2eBnB42UGY9hWJhHE2EtCma9D3lSkoiKvrhFXqfNjlWe5ootUCU8z_UrRlBh-hT7WsXUX3GFeO8J49tV_-g6nQwBVsj86Hevyg4_tvo1uHvXCrQPgE2p1Iy-C1CsF6i1zV6vUSvl-grz17xNsxmDmn5pzD-p-oXhzKvtA
CitedBy_id crossref_primary_10_1016_j_bmc_2021_116203
crossref_primary_10_1016_j_freeradbiomed_2020_10_304
crossref_primary_10_18632_oncotarget_24632
crossref_primary_10_1590_1414_431x2020e10931
crossref_primary_10_1016_j_fsi_2019_03_010
crossref_primary_10_1089_ars_2017_7426
crossref_primary_10_1016_j_semcancer_2020_05_001
crossref_primary_10_26508_lsa_202101084
crossref_primary_10_3390_antiox9080701
crossref_primary_10_1016_j_yexcr_2024_113925
crossref_primary_10_1080_08880018_2018_1467986
crossref_primary_10_18632_oncotarget_23662
crossref_primary_10_1158_1541_7786_MCR_20_0172
crossref_primary_10_3390_antiox12010046
crossref_primary_10_1016_j_fsi_2023_108781
crossref_primary_10_3390_molecules27238301
crossref_primary_10_1155_2020_1276328
crossref_primary_10_1016_j_arr_2018_03_005
crossref_primary_10_1186_s13058_018_0984_0
crossref_primary_10_1016_j_ijbiomac_2020_05_168
crossref_primary_10_1186_s40364_019_0168_9
crossref_primary_10_1530_ERC_18_0476
crossref_primary_10_3389_fmolb_2022_883297
crossref_primary_10_2174_0113892029273682240111052317
crossref_primary_10_1016_j_freeradbiomed_2021_10_010
crossref_primary_10_3389_fmolb_2022_889719
crossref_primary_10_1016_j_ijbiomac_2022_04_086
crossref_primary_10_1111_exd_14900
crossref_primary_10_3390_cancers11040439
crossref_primary_10_3390_cancers10090305
crossref_primary_10_3390_molecules22111818
crossref_primary_10_1016_j_dnarep_2019_03_001
crossref_primary_10_1016_j_dnarep_2020_103027
crossref_primary_10_1038_s41551_021_00752_7
crossref_primary_10_1016_j_phymed_2022_153932
crossref_primary_10_1089_ars_2017_7404
crossref_primary_10_1292_jvms_22_0102
crossref_primary_10_1089_ars_2021_0068
crossref_primary_10_3390_cells12131713
crossref_primary_10_1016_j_prp_2021_153351
crossref_primary_10_3390_biomedicines12030502
crossref_primary_10_1016_j_freeradbiomed_2023_11_009
crossref_primary_10_1016_j_wneu_2022_09_024
crossref_primary_10_2174_0929866528666211105105953
crossref_primary_10_1016_j_tcb_2025_01_006
crossref_primary_10_3390_endocrines3010013
crossref_primary_10_1016_j_isci_2022_105793
crossref_primary_10_3390_cimb45020114
crossref_primary_10_3390_cancers12071830
crossref_primary_10_1186_s12964_019_0493_5
crossref_primary_10_2147_CMAR_S319048
crossref_primary_10_3390_antiox8030063
crossref_primary_10_1080_07391102_2023_2252076
crossref_primary_10_1002_wrna_1594
crossref_primary_10_1007_s00403_024_03453_8
crossref_primary_10_1038_s41598_024_58216_2
crossref_primary_10_1016_j_bcp_2023_115444
crossref_primary_10_1021_acs_chemrev_9b00371
crossref_primary_10_1038_s41416_018_0375_4
crossref_primary_10_1186_s12967_017_1357_7
crossref_primary_10_1016_j_fsi_2019_03_062
crossref_primary_10_1186_s12885_019_6046_x
crossref_primary_10_7759_cureus_66117
crossref_primary_10_1002_jcp_26302
crossref_primary_10_3390_proteomes8040032
crossref_primary_10_1371_journal_pone_0242465
crossref_primary_10_1016_j_jpba_2023_115398
crossref_primary_10_3389_fvets_2021_666512
crossref_primary_10_1016_j_fsi_2019_10_001
crossref_primary_10_3390_molecules24224067
crossref_primary_10_1155_2018_2389523
crossref_primary_10_1177_0960327120969968
crossref_primary_10_3389_fphar_2023_1333507
crossref_primary_10_1002_jbt_70162
crossref_primary_10_3390_antiox8010015
crossref_primary_10_3390_antiox8100471
crossref_primary_10_1021_acs_analchem_8b01992
crossref_primary_10_1093_gerona_gly113
crossref_primary_10_3390_ijms20123046
crossref_primary_10_1172_JCI120844
crossref_primary_10_3390_antiox12081617
crossref_primary_10_3390_ijms26020799
crossref_primary_10_15430_JCP_2019_24_2_65
crossref_primary_10_1186_s12958_018_0396_0
crossref_primary_10_1093_femsle_fnab077
crossref_primary_10_1016_j_rechem_2024_101931
crossref_primary_10_1093_hmg_ddac218
crossref_primary_10_1016_j_jtemb_2022_127115
crossref_primary_10_1080_14789450_2018_1491796
crossref_primary_10_3390_antiox12040901
crossref_primary_10_1194_jlr_R082578
crossref_primary_10_3390_pharmaceutics14091945
crossref_primary_10_1002_ctm2_810
crossref_primary_10_1016_j_archoralbio_2019_104537
crossref_primary_10_3892_ol_2024_14461
crossref_primary_10_1515_hsz_2021_0341
crossref_primary_10_1186_s12935_022_02845_y
crossref_primary_10_1186_s12014_023_09419_8
crossref_primary_10_3390_cancers16020292
crossref_primary_10_3390_cells11111772
crossref_primary_10_1016_j_cbi_2019_02_030
crossref_primary_10_1515_hsz_2018_0327
crossref_primary_10_3390_cells12020256
crossref_primary_10_1016_j_fsi_2020_10_007
crossref_primary_10_3390_ph15060711
crossref_primary_10_1016_j_ejphar_2023_175612
crossref_primary_10_3390_ijms20184407
crossref_primary_10_3390_molecules26247658
crossref_primary_10_1089_ars_2022_0074
crossref_primary_10_3390_cancers16010081
crossref_primary_10_3390_cancers14235857
crossref_primary_10_1002_adtp_202100040
crossref_primary_10_1002_mc_23831
crossref_primary_10_1016_j_bbamcr_2019_04_007
crossref_primary_10_1186_s40709_021_00153_6
crossref_primary_10_3389_fmicb_2022_811258
crossref_primary_10_3390_molecules28227501
crossref_primary_10_1016_j_jcmgh_2020_12_013
crossref_primary_10_1590_s2175_97902018000417751
crossref_primary_10_1155_2019_5268031
crossref_primary_10_1155_2020_8359860
crossref_primary_10_1016_j_phyplu_2021_100148
crossref_primary_10_3390_biom10101429
crossref_primary_10_1002_tox_23915
crossref_primary_10_3389_fonc_2022_923009
crossref_primary_10_1016_j_drup_2018_11_001
crossref_primary_10_1038_s41416_021_01510_x
crossref_primary_10_1016_j_tranon_2018_11_014
crossref_primary_10_1071_RD19310
crossref_primary_10_1186_s12935_021_02064_x
Cites_doi 10.1021/pr201172n
10.1074/jbc.M001001200
10.1158/0008-5472.CAN-06-2401
10.1111/IGC.0b013e3181ad0f0d
10.1111/j.1432-1033.1997.t01-1-00052.x
10.1177/1534735407309760
10.1111/bpa.12014
10.1016/j.bbrc.2012.03.103
10.1089/ars.2000.2.4-801
10.1038/nchembio.1695
10.1007/s11010-013-1891-4
10.3109/07357907.2010.535056
10.1016/j.coph.2007.04.007
10.1186/1741-7015-9-137
10.1016/j.yexcr.2006.05.006
10.1073/pnas.91.15.7017
10.1016/j.freeradbiomed.2005.02.026
10.1089/thy.2005.15.205
10.1016/j.biocel.2014.04.024
10.1186/bcr3691
10.1089/ars.2012.4713
10.1677/ERC-09-0269
10.1038/emboj.2009.101
10.1126/science.1080405
10.1089/ars.1999.1.4-385
10.1016/S0021-9258(18)68840-4
10.1016/j.ejso.2014.11.037
10.1038/35025109
10.1007/978-1-4020-6051-9_3
10.1126/stke.2000.53.pe1
10.1016/j.freeradbiomed.2014.10.009
10.1371/journal.pone.0144851
10.3892/ijo.2014.2398
10.1038/onc.2012.93
10.1016/j.biocel.2006.07.001
10.1074/jbc.M109.016071
10.1016/S0022-5347(05)00659-2
10.1089/ars.2010.3412
10.1089/ars.2010.3624
10.1016/j.bbaexp.2007.05.004
10.4161/cc.8.24.10242
10.1182/blood-2011-02-336446
10.1016/j.freeradbiomed.2008.01.013
10.1007/s00401-008-0373-3
10.4049/jimmunol.175.12.8424
10.1111/j.1349-7006.2008.00912.x
10.1074/jbc.270.48.28635
10.1038/sj.bjc.6604975
10.1158/0008-5472.CAN-06-0157
10.1007/s00268-008-9521-0
10.18632/oncotarget.6435
10.1021/pr200141c
10.1515/BC.2002.040
10.1073/pnas.0700481104
10.1016/S0304-3835(99)00243-8
10.1007/s00432-011-1119-5
10.1038/nrd4002
10.3390/ijms12107163
10.1006/jmbi.2001.4853
10.1089/ars.2011.4421
10.1007/s00432-011-0992-2
10.1111/j.1742-4658.2007.06103.x
10.1016/j.febslet.2012.06.003
10.1152/ajpcell.00540.2007
10.1089/ars.2010.3393
10.1002/pros.21292
10.1111/his.12389
10.1074/jbc.C400496200
10.3892/mmr.2014.2316
10.1016/j.bbagen.2010.07.004
10.1016/j.ejca.2010.02.006
10.1155/2015/654594
10.1007/s00018-009-0099-y
10.3164/jcbn.11-109
10.1007/s10517-012-1849-7
10.1016/j.bcp.2014.07.017
10.1186/1471-2407-11-262
10.1021/pr900811x
10.1007/s00432-015-1916-3
10.1016/j.canlet.2008.02.031
10.1158/1078-0432.CCR-07-4457
10.3892/mco.2014.317
10.1007/s00401-011-0867-2
10.1073/pnas.1013012108
10.1016/j.freeradbiomed.2008.09.027
10.1093/jb/mvq156
10.3904/kjim.2011.26.3.304
10.1021/bi301017s
10.2174/0929867311320999165
10.1002/path.1042
10.1016/j.canlet.2015.07.002
10.1074/jbc.M001943200
10.1038/nature09702
10.1530/ERC-11-0360
10.1371/journal.pone.0016340
10.1186/bcr1789
10.1002/prot.22936
10.1080/01635580701365043
10.3892/br.2012.43
10.1158/1535-7163.MCT-09-0904
10.1016/j.freeradbiomed.2015.01.025
10.1074/jbc.273.11.6303
10.1179/135100002125000352
10.1080/15216540252774748
10.1158/0008-5472.CAN-07-6817
10.1089/ars.2012.4634
10.1007/978-1-4020-6051-9_15
10.1515/bchm.1997.378.8.827
10.1016/j.pharmthera.2016.03.018
10.1093/oxfordjournals.jbchem.a022632
10.1016/j.febslet.2009.05.029
10.1021/bi012173m
10.1016/j.canlet.2008.02.029
10.1016/j.ejmech.2015.04.040
10.1371/journal.pone.0105529
10.1136/jclinpath-2014-202771
10.3748/wjg.v21.i38.10840
10.1111/j.1365-2443.2010.01473.x
10.1038/nsb0598-400
10.1155/2014/209845
10.1371/journal.pone.0050394
10.1186/1471-213X-7-125
10.1016/j.cell.2011.02.013
10.1038/cddis.2011.121
10.1152/physrev.00018.2001
10.1038/nrm2240
10.1038/nature11088
10.1038/emm.2015.24
10.1016/j.febslet.2014.07.030
10.1016/j.ydbio.2007.07.036
10.1155/2010/214074
10.1021/pr200311p
10.1007/s12035-014-8885-4
10.3892/ijo.2013.2208
10.1038/sj.onc.1208821
10.3233/CBM-2009-0604
10.1155/2012/762825
10.1007/s12192-013-0442-y
10.1530/EJE-11-0856
10.1073/pnas.1401100111
10.1016/j.canlet.2008.12.011
10.1074/jbc.M807564200
10.1006/bbrc.1997.6564
10.1093/carcin/bgp104
10.1038/nrc2981
10.1016/j.breast.2013.02.008
10.1158/0008-5472.CAN-12-4226
10.1038/nchembio.85
10.3892/or.2013.2714
10.1016/j.canlet.2008.02.044
10.1038/nature01819
10.1053/j.gastro.2015.06.007
10.1089/ars.2010.3584
10.33549/physiolres.931844
ContentType Journal Article
Copyright COPYRIGHT 2017 Spandidos Publications
Copyright Spandidos Publications UK Ltd. 2017
Copyright: © Nicolussi et al. 2017
Copyright_xml – notice: COPYRIGHT 2017 Spandidos Publications
– notice: Copyright Spandidos Publications UK Ltd. 2017
– notice: Copyright: © Nicolussi et al. 2017
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.3892/mco.2017.1129
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
British Nursing Index with Full Text
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
ProQuest One Health & Nursing
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central (New)
ProQuest One Academic
ProQuest Central (Alumni)
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

ProQuest One Academic Middle East (New)


PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 2049-9469
EndPage 153
ExternalDocumentID PMC5351761
A493448161
28357082
10_3892_mco_2017_1129
Genre Journal Article
GroupedDBID 0R~
53G
7X7
8FI
8FJ
AAYXX
ABDBF
ABUWG
ACGFS
ACUHS
ADBBV
AFKRA
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AN0
BENPR
BNQBC
BPHCQ
BVXVI
C45
CCPQU
CITATION
EBD
EBS
EJD
ESX
FYUFA
H13
HMCUK
HUR
HZ~
IAO
IHR
IPNFZ
ITC
O9-
OK1
OVD
PHGZM
PHGZT
PPXIY
PQQKQ
PROAC
RIG
RPM
TEORI
UKHRP
3V.
NPM
PMFND
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c412t-3fd402297e605afb464e15d66f636deb5cdda3bd3e61f3bffd2be7183e2a7ae33
IEDL.DBID 7X7
ISSN 2049-9450
IngestDate Thu Aug 21 14:12:04 EDT 2025
Fri Sep 05 08:26:18 EDT 2025
Fri Jul 25 23:07:22 EDT 2025
Tue Jun 17 21:50:54 EDT 2025
Tue Jun 10 20:46:55 EDT 2025
Thu Jan 02 22:22:34 EST 2025
Tue Aug 05 12:04:08 EDT 2025
Thu Apr 24 22:52:11 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 2
Keywords chemosensitization
chemoresistance
tumorigenesis
peroxiredoxins
oxidative stress
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c412t-3fd402297e605afb464e15d66f636deb5cdda3bd3e61f3bffd2be7183e2a7ae33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC5351761
PMID 28357082
PQID 1994977244
PQPubID 2044956
PageCount 15
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5351761
proquest_miscellaneous_1882497716
proquest_journals_1994977244
gale_infotracmisc_A493448161
gale_infotracacademiconefile_A493448161
pubmed_primary_28357082
crossref_primary_10_3892_mco_2017_1129
crossref_citationtrail_10_3892_mco_2017_1129
PublicationCentury 2000
PublicationDate 2017-02-01
PublicationDateYYYYMMDD 2017-02-01
PublicationDate_xml – month: 02
  year: 2017
  text: 2017-02-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Athens
PublicationTitle Molecular and clinical oncology
PublicationTitleAlternate Mol Clin Oncol
PublicationYear 2017
Publisher Spandidos Publications
Spandidos Publications UK Ltd
D.A. Spandidos
Publisher_xml – name: Spandidos Publications
– name: Spandidos Publications UK Ltd
– name: D.A. Spandidos
References Xi (key20180107152254_b101-mco-0-0-1129) 2014; 588
Okado-Matsumoto (key20180107152254_b108-mco-0-0-1129) 2000; 127
Krstić (key20180107152254_b42-mco-0-0-1129) 2015; 2015
Ha (key20180107152254_b71-mco-0-0-1129) 2012; 421
Gorrini (key20180107152254_b153-mco-0-0-1129) 2013; 12
Barranco-Medina (key20180107152254_b31-mco-0-0-1129) 2009; 583
Kim (key20180107152254_b52-mco-0-0-1129) 2007; 67
Pisoschi (key20180107152254_b33-mco-0-0-1129) 2015; 97
Riddell (key20180107152254_b69-mco-0-0-1129) 2012; 7
O'Leary (key20180107152254_b57-mco-0-0-1129) 2014; 16
Zhang (key20180107152254_b142-mco-0-0-1129) 2011; 10
Bryk (key20180107152254_b10-mco-0-0-1129) 2000; 407
Ummanni (key20180107152254_b104-mco-0-0-1129) 2012; 11
Schremmer (key20180107152254_b143-mco-0-0-1129) 2007; 44
Cairns (key20180107152254_b47-mco-0-0-1129) 2011; 11
Rhee (key20180107152254_b21-mco-0-0-1129) 2005; 38
Kwee (key20180107152254_b50-mco-0-0-1129) 2014; 2014
Duracková (key20180107152254_b2-mco-0-0-1129) 2010; 59
Rhee (key20180107152254_b25-mco-0-0-1129) 2001; 52
Chang (key20180107152254_b116-mco-0-0-1129) 2011; 10
Xing (key20180107152254_b3-mco-0-0-1129) 2012; 19
Clerkin (key20180107152254_b41-mco-0-0-1129) 2008; 266
Choi (key20180107152254_b102-mco-0-0-1129) 2002; 22
Chhunchha (key20180107152254_b135-mco-0-0-1129) 2011; 2
Hall (key20180107152254_b19-mco-0-0-1129) 2011; 15
Miranda-Vizuete (key20180107152254_b96-mco-0-0-1129) 2000; 2
Seibold (key20180107152254_b151-mco-0-0-1129) 2013; 22
Zhou (key20180107152254_b64-mco-0-0-1129) 2015; 8
Yi (key20180107152254_b119-mco-0-0-1129) 2014; 2
Graves (key20180107152254_b124-mco-0-0-1129) 2009; 284
Zhu (key20180107152254_b111-mco-0-0-1129) 2014; 9
Mishra (key20180107152254_b113-mco-0-0-1129) 2015; 366
Kim (key20180107152254_b89-mco-0-0-1129) 2009; 21
Winterbourn (key20180107152254_b13-mco-0-0-1129) 2008; 4
Cao (key20180107152254_b56-mco-0-0-1129) 2009; 28
Stresing (key20180107152254_b93-mco-0-0-1129) 2013; 32
He (key20180107152254_b100-mco-0-0-1129) 2012; 586
Park (key20180107152254_b58-mco-0-0-1129) 2013; 19
Shukla (key20180107152254_b145-mco-0-0-1129) 2009; 5
Kim (key20180107152254_b60-mco-0-0-1129) 2008; 14
Lee (key20180107152254_b85-mco-0-0-1129) 2013; 73
Kubo (key20180107152254_b140-mco-0-0-1129) 2008; 294
Kropotov (key20180107152254_b164-mco-0-0-1129) 2006; 312
Du (key20180107152254_b72-mco-0-0-1129) 2010; 17
Wu (key20180107152254_b136-mco-0-0-1129) 2015; 10
Rhee (key20180107152254_b6-mco-0-0-1129) 2000; 2000
Quan (key20180107152254_b61-mco-0-0-1129) 2006; 175
Yanagawa (key20180107152254_b74-mco-0-0-1129) 1999; 145
Olmos (key20180107152254_b97-mco-0-0-1129) 2013; 19
Schulte (key20180107152254_b107-mco-0-0-1129) 2011; 9
Nguyên-Nhu (key20180107152254_b123-mco-0-0-1129) 2007; 1769
Huo (key20180107152254_b82-mco-0-0-1129) 2008; 44
Thélie (key20180107152254_b53-mco-0-0-1129) 2007; 7
Lu (key20180107152254_b94-mco-0-0-1129) 2014; 387
Pak (key20180107152254_b159-mco-0-0-1129) 2011; 29
O'Neill (key20180107152254_b77-mco-0-0-1129) 2011; 469
Wei (key20180107152254_b120-mco-0-0-1129) 2011; 108
Chowdhury (key20180107152254_b132-mco-0-0-1129) 2014; 20
Watabe (key20180107152254_b95-mco-0-0-1129) 1997; 249
Fiaschi (key20180107152254_b44-mco-0-0-1129) 2012; 2012
Dröge (key20180107152254_b4-mco-0-0-1129) 2002; 82
Patel (key20180107152254_b38-mco-0-0-1129) 2007; 6
Kropotov (key20180107152254_b125-mco-0-0-1129) 2007; 274
Zhang (key20180107152254_b91-mco-0-0-1129) 2012; 138
Kim (key20180107152254_b14-mco-0-0-1129) 1988; 263
Hellman (key20180107152254_b88-mco-0-0-1129) 2009; 100
Rhee (key20180107152254_b81-mco-0-0-1129) 2011; 15
Karihtala (key20180107152254_b117-mco-0-0-1129) 2011; 11
Khandrika (key20180107152254_b37-mco-0-0-1129) 2009; 282
Giorgio (key20180107152254_b5-mco-0-0-1129) 2007; 8
Ren (key20180107152254_b63-mco-0-0-1129) 2013; 30
Li (key20180107152254_b163-mco-0-0-1129) 2015; 141
Szatrowski (key20180107152254_b39-mco-0-0-1129) 1991; 51
Shiota (key20180107152254_b126-mco-0-0-1129) 2008; 99
Fatma (key20180107152254_b134-mco-0-0-1129) 2009; 284
Power (key20180107152254_b137-mco-0-0-1129) 2008; 115
Ishii (key20180107152254_b112-mco-0-0-1129) 2012; 50
Yang (key20180107152254_b154-mco-0-0-1129) 2013; 20
Kamiguti (key20180107152254_b35-mco-0-0-1129) 2005; 175
Karplus (key20180107152254_b12-mco-0-0-1129) 2015; 80
Seo (key20180107152254_b22-mco-0-0-1129) 2000; 275
Roumes (key20180107152254_b109-mco-0-0-1129) 2010; 30
Knoops (key20180107152254_b122-mco-0-0-1129) 2011; 15
Nelson (key20180107152254_b17-mco-0-0-1129) 2011; 79
Taguchi (key20180107152254_b49-mco-0-0-1129) 2011; 16
Thongwatchara (key20180107152254_b141-mco-0-0-1129) 2011; 26
Gérard (key20180107152254_b128-mco-0-0-1129) 2005; 15
Ushio-Fukai (key20180107152254_b43-mco-0-0-1129) 2008; 266
Valko (key20180107152254_b1-mco-0-0-1129) 2007; 39
Tsao (key20180107152254_b36-mco-0-0-1129) 2007; 59
Chang (key20180107152254_b147-mco-0-0-1129) 2007; 9
Neumann (key20180107152254_b54-mco-0-0-1129) 2003; 424
Cho (key20180107152254_b78-mco-0-0-1129) 2014; 111
Furuta (key20180107152254_b84-mco-0-0-1129) 2006; 66
Chung (key20180107152254_b62-mco-0-0-1129) 2010; 9
Chung (key20180107152254_b156-mco-0-0-1129) 2001; 21
Monteiro (key20180107152254_b28-mco-0-0-1129) 2007; 104
Ikeda (key20180107152254_b110-mco-0-0-1129) 2011; 149
Nogoceke (key20180107152254_b9-mco-0-0-1129) 1997; 378
Park (key20180107152254_b48-mco-0-0-1129) 2016; 163
Hillas (key20180107152254_b11-mco-0-0-1129) 2000; 275
Hofmann (key20180107152254_b26-mco-0-0-1129) 2002; 383
Kinnula (key20180107152254_b67-mco-0-0-1129) 2002; 196
Cai (key20180107152254_b66-mco-0-0-1129) 2015; 41
Park (key20180107152254_b144-mco-0-0-1129) 2011; 137
Butterfield (key20180107152254_b165-mco-0-0-1129) 1999; 1
Li (key20180107152254_b99-mco-0-0-1129) 2013; 23
Neumann (key20180107152254_b51-mco-0-0-1129) 2009; 8
Declercq (key20180107152254_b27-mco-0-0-1129) 2001; 311
Yun (key20180107152254_b138-mco-0-0-1129) 2015; 52
Sofiadis (key20180107152254_b149-mco-0-0-1129) 2012; 166
Sun (key20180107152254_b65-mco-0-0-1129) 2015; 21
Woo (key20180107152254_b167-mco-0-0-1129) 2005; 280
Nishikawa (key20180107152254_b40-mco-0-0-1129) 2008; 266
Kalinina (key20180107152254_b157-mco-0-0-1129) 2012; 153
Fulda (key20180107152254_b34-mco-0-0-1129) 2010; 2010
Karihtala (key20180107152254_b118-mco-0-0-1129) 2009; 19
Fernandez-Ranvier (key20180107152254_b129-mco-0-0-1129) 2008; 32
Wang (key20180107152254_b155-mco-0-0-1129) 2014; 6
Weinberg (key20180107152254_b46-mco-0-0-1129) 2009; 66
Song (key20180107152254_b73-mco-0-0-1129) 2009; 30
Hu (key20180107152254_b106-mco-0-0-1129) 2013; 1
Song (key20180107152254_b98-mco-0-0-1129) 2015; 149
Chen (key20180107152254_b114-mco-0-0-1129) 2009; 8
Karihtala (key20180107152254_b103-mco-0-0-1129) 2003; 9
Fisher (key20180107152254_b130-mco-0-0-1129) 2011; 15
Wood (key20180107152254_b30-mco-0-0-1129) 2002; 41
Cha (key20180107152254_b7-mco-0-0-1129) 1995; 270
Hanahan (key20180107152254_b45-mco-0-0-1129) 2011; 144
Palande (key20180107152254_b121-mco-0-0-1129) 2011; 6
Chowdhury (key20180107152254_b133-mco-0-0-1129) 2009; 46
Dammeyer (key20180107152254_b20-mco-0-0-1129) 2011; 1810
McDonald (key20180107152254_b161-mco-0-0-1129) 2014; 45
Fujii (key20180107152254_b24-mco-0-0-1129) 2015; 83
Karplus (key20180107152254_b29-mco-0-0-1129) 2007; 44
Kwon (key20180107152254_b160-mco-0-0-1129) 2015; 47
Neumann (key20180107152254_b166-mco-0-0-1129) 2007; 7
Trzeciecka (key20180107152254_b92-mco-0-0-1129) 2016; 7
Jiang (key20180107152254_b70-mco-0-0-1129) 2014; 4
Feng (key20180107152254_b86-mco-0-0-1129) 2014; 10
El Eter (key20180107152254_b139-mco-0-0-1129) 2014; 19
Fujii (key20180107152254_b32-mco-0-0-1129) 2002; 7
Edgar (key20180107152254_b16-mco-0-0-1129) 2012; 485
Barbosa (key20180107152254_b83-mco-0-0-1129) 2007; 310
Glasauer (key20180107152254_b152-mco-0-0-1129) 2014; 92
Pylväs (key20180107152254_b87-mco-0-0-1129) 2010; 46
Nicolussi (key20180107152254_b75-mco-0-0-1129) 2014; 44
Choi (key20180107152254_b131-mco-0-0-1129) 1998; 5
Godfrey (key20180107152254_b59-mco-0-0-1129) 2012; 119
Wood (key20180107152254_b76-mco-0-0-1129) 2003; 300
Basu (key20180107152254_b90-mco-0-0-1129) 2011; 71
Ho (key20180107152254_b150-mco-0-0-1129) 2010; 9
Raatikainen (key20180107152254_b148-mco-0-0-1129) 2015; 35
Kang (key20180107152254_b23-mco-0-0-1129) 1998; 273
Pritchard (key20180107152254_b115-mco-0-0-1129) 2009; 69
Kuusisto (key20180107152254_b146-mco-0-0-1129) 2015; 68
Svendsen (key20180107152254_b68-mco-0-0-1129) 2011; 122
Sobotta (key20180107152254_b80-mco-0-0-1129) 2015; 11
Park (key20180107152254_b158-mco-0-0-1129) 2000; 6
Perkins (key20180107152254_b18-mco-0-0-1129) 2012; 51
Avitabile (key20180107152254_b79-mco-0-0-1129) 2014; 53
Kim (key20180107152254_b105-mco-0-0-1129) 2011; 26
Zhou (key20180107152254_b8-mco-0-0-1129) 1997; 233
Song (key20180107152254_b162-mco-0-0-1129) 2011; 12
Chae (key20180107152254_b15-mco-0-0-1129) 1994; 91
Egler (key20180107152254_b55-mco-0-0-1129) 2005; 24
Bur (key20180107152254_b127-mco-0-0-1129) 2014; 65
16339585 - J Immunol. 2005 Dec 15;175(12):8424-30
20977338 - Antioxid Redox Signal. 2011 Aug 1;15(3):817-29
20647035 - Biochim Biophys Acta. 2011 Jan;1810(1):111-38
18386021 - Acta Neuropathol. 2008 Jun;115(6):611-22
20969484 - Antioxid Redox Signal. 2011 Aug 1;15(3):795-815
25078786 - Biochem Pharmacol. 2014 Nov 1;92(1):90-101
9168946 - Biochem Biophys Res Commun. 1997 Apr 28;233(3):848-52
25092340 - Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12043-8
18275859 - Free Radic Biol Med. 2008 Apr 15;44(8):1578-91
19367286 - Br J Cancer. 2009 Apr 21;100(8):1303-14
20206498 - Eur J Cancer. 2010 Jun;46(9):1661-7
16170382 - Oncogene. 2005 Dec 1;24(54):8038-50
9377478 - Biol Chem. 1997 Aug;378(8):827-36
22016591 - Korean J Intern Med. 2011 Sep;26(3):304-13
26021759 - Exp Mol Med. 2015 May 29;47:e165
22438257 - Blood. 2012 May 10;119(19):4499-511
24920174 - Mol Med Rep. 2014 Aug;10(2):867-73
23815338 - Antioxid Redox Signal. 2014 Jan 20;20(3):391-402
24800215 - Biomed Res Int. 2014;2014:209845
20410161 - Endocr Relat Cancer. 2010 Jun 03;17 (3):553-60
25875582 - J Cancer Res Clin Oncol. 2015 Dec;141(12):2071-7
17234762 - Cancer Res. 2007 Jan 15;67(2):546-54
17360337 - Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4886-91
22196027 - BMC Med. 2011 Dec 23;9:137
21287625 - Proteins. 2011 Mar;79(3):947-64
21212070 - J Biochem. 2011 Apr;149(4):443-53
22430214 - Oncogene. 2013 Feb 7;32(6):724-35
24814289 - Int J Biochem Cell Biol. 2014 Aug;53:24-34
15917183 - Free Radic Biol Med. 2005 Jun 15;38(12):1543-52
12891360 - Nature. 2003 Jul 31;424(6948):561-5
26617696 - Int J Clin Exp Pathol. 2015 Sep 01;8(9):9863-74
12033427 - Biol Chem. 2002 Mar-Apr;383(3-4):347-64
24648924 - Biomed Rep. 2013 Mar;1(2):228-230
21283726 - PLoS One. 2011 Jan 20;6(1):e16340
23461683 - Antioxid Redox Signal. 2013 Nov 1;19(13):1507-21
24698430 - Histopathology. 2014 Sep;65(3):319-27
11213484 - Antioxid Redox Signal. 2000 Winter;2(4):801-10
22424448 - J Proteome Res. 2012 Apr 6;11(4):2452-66
25232487 - Am J Cancer Res. 2014 Sep 06;4(5):445-60
9363753 - Eur J Biochem. 1997 Oct 1;249(1):52-60
22113199 - Cell Death Dis. 2011 Nov 24;2:e234
26078812 - Oxid Med Cell Longev. 2015;2015:654594
11518528 - J Mol Biol. 2001 Aug 24;311(4):751-9
18413821 - Clin Cancer Res. 2008 Apr 15;14(8):2326-33
21251164 - Genes Cells. 2011 Feb;16(2):123-40
19357035 - Hepatobiliary Pancreat Dis Int. 2009 Apr;8(2):193-200
22475482 - Biochem Biophys Res Commun. 2012 Apr 27;421(1):33-7
26478675 - World J Gastroenterol. 2015 Oct 14;21(38):10840-52
20182529 - Int J Cell Biol. 2010;2010:214074
18362051 - Cancer Lett. 2008 Jul 18;266(1):53-9
12189041 - Redox Rep. 2002;7(3):123-30
23185615 - PLoS One. 2012;7(11):e50394
23749642 - Cancer Res. 2013 Aug 1;73(15):4744-57
21487000 - Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7004-9
24009050 - Oncol Rep. 2013 Nov;30(5):2297-303
19464293 - FEBS Lett. 2009 Jun 18;583(12):1809-16
21503584 - Oncol Rep. 2011 Jul;26(1):185-91
20919932 - Antioxid Redox Signal. 2011 Aug 1;15(3):831-44
19820366 - Int J Gynecol Cancer. 2009 Aug;19(6):1047-51
26637857 - Anticancer Res. 2015 Dec;35(12):6465-70
27130805 - Pharmacol Ther. 2016 Jul;163:1-23
18973804 - Free Radic Biol Med. 2009 Jan 15;46(2):146-53
24287781 - Nat Rev Drug Discov. 2013 Dec;12(12):931-47
17628720 - Biochim Biophys Acta. 2007 Jul-Aug;1769(7-8):472-83
22666258 - Int J Cell Biol. 2012;2012:762825
9587003 - Nat Struct Biol. 1998 May;5(5):400-6
25942353 - Eur J Med Chem. 2015 Jun 5;97:55-74
22710126 - FEBS Lett. 2012 Jul 30;586(16):2451-8
25193021 - Mol Neurobiol. 2015 Aug;52(1):422-31
16778180 - Cancer Res. 2006 Jun 15;66(12):6080-6
19902980 - J Proteome Res. 2010 Jan;9(1):451-7
18084889 - Subcell Biochem. 2007;44:41-60
23489758 - Breast. 2013 Oct;22(5):817-23
15590625 - J Biol Chem. 2005 Feb 4;280(5):3125-8
21693047 - BMC Cancer. 2011 Jun 21;11:262
12714747 - Science. 2003 Apr 25;300(5619):650-3
21517111 - J Proteome Res. 2011 Jun 3;10(6):2863-72
21166495 - Cancer Invest. 2011 Jan;29(1):21-8
25011585 - Breast Cancer Res. 2014 Jul 10;16(4):R79
21691750 - J Cancer Res Clin Oncol. 2011 Aug;137(8):1229-38
17988387 - BMC Dev Biol. 2007 Nov 07;7:125
19406930 - Carcinogenesis. 2009 Jul;30(7):1106-14
23862622 - Curr Med Chem. 2013;20(30):3677-92
25137134 - PLoS One. 2014 Aug 19;9(8):e105529
8041738 - Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7017-21
26636537 - Oncotarget. 2016 Jan 12;7(2):1717-31
25093297 - FEBS Lett. 2014 Sep 17;588(18):3390-4
11969410 - Biochemistry. 2002 Apr 30;41(17):5493-504
25452140 - Free Radic Biol Med. 2015 Mar;80:183-90
18324346 - World J Surg. 2008 May;32(5):873-81
25935550 - J Clin Pathol. 2015 Jul;68(7):552-6
24234423 - Mol Cell Biochem. 2014 Feb;387(1-2):261-70
11773609 - Physiol Rev. 2002 Jan;82(1):47-95
17700625 - Nat Rev Mol Cell Biol. 2007 Sep;8(9):722-8
10766746 - J Biol Chem. 2000 Jun 23;275(25):18801-9
16978905 - Int J Biochem Cell Biol. 2007;39(1):44-84
18084901 - Subcell Biochem. 2007;44:317-44
21258394 - Nat Rev Cancer. 2011 Feb;11(2):85-95
19629388 - Cell Mol Life Sci. 2009 Dec;66(23):3663-73
26091938 - Gastroenterology. 2015 Oct;149(4):1006-16.e9
11795591 - IUBMB Life. 2001 Jul;52(1-2):35-41
19223557 - Cancer Res. 2009 Mar 1;69(5):1739-47
23113308 - Bull Exp Biol Med. 2012 Oct;153(6):878-81
21270888 - Nature. 2011 Jan 27;469(7331):498-503
22143496 - Endocr Relat Cancer. 2012 Jan 09;19(1):C7-11
10530780 - Cancer Lett. 1999 Oct 18;145(1-2):127-32
19016754 - Cancer Sci. 2008 Oct;99(10):1950-9
11396151 - Anticancer Res. 2001 Mar-Apr;21(2A):1129-33
19923889 - Cell Cycle. 2009 Dec 15;8(24):4072-8
24976757 - Breast Cancer (Dove Med Press). 2014 May 23;6:73-80
10751410 - J Biol Chem. 2000 Jul 7;275(27):20346-54
11752613 - Sci STKE. 2000 Oct 10;2000(53):pe1
26659441 - PLoS One. 2015 Dec 14;10(12):e0144851
22928725 - Biochemistry. 2012 Sep 25;51(38):7638-50
23801458 - Cell Stress Chaperones. 2014 Mar;19(2):173-81
19407367 - Cancer Biomark. 2009;5(3):127-35
11001062 - Nature. 2000 Sep 14;407(6801):211-5
22448089 - J Clin Biochem Nutr. 2012 Mar;50(2):91-105
17937766 - FEBS J. 2007 Nov;274(22):5804-14
11156252 - Clin Cancer Res. 2000 Dec;6(12):4915-20
19553668 - J Biol Chem. 2009 Aug 21;284(34):22758-72
20354123 - Mol Cancer Ther. 2010 Apr;9(4):825-32
2895105 - J Biol Chem. 1988 Apr 5;263(10):4704-11
23186333 - Antioxid Redox Signal. 2013 Aug 10;19(5):482-96
25402766 - Nat Chem Biol. 2015 Jan;11(1):64-70
21031435 - Prostate. 2011 May 15;71(7):755-65
10731722 - J Biochem. 2000 Mar;127(3):493-501
25656995 - Free Radic Biol Med. 2015 Jun;83:373-9
7499381 - J Biol Chem. 1995 Dec 1;270(48):28635-41
22275472 - Eur J Endocrinol. 2012 Apr;166(4):657-67
12960131 - Clin Cancer Res. 2003 Aug 15;9(9):3418-24
22072940 - Int J Mol Sci. 2011;12(10):7163-85
15785239 - Thyroid. 2005 Mar;15(3):205-9
1846317 - Cancer Res. 1991 Feb 1;51(3):794-8
17764670 - Dev Biol. 2007 Oct 1;310(1):154-68
16781710 - Exp Cell Res. 2006 Sep 10;312(15):2806-15
18421291 - Nat Chem Biol. 2008 May;4(5):278-86
21187494 - Anticancer Res. 2010 Dec;30(12):5085-9
25054044 - Mol Clin Oncol. 2014 Sep;2(5):767-772
22622569 - Nature. 2012 May 16;485(7399):459-64
21376230 - Cell. 2011 Mar 4;144(5):646-74
19369943 - EMBO J. 2009 May 20;28(10 ):1505-17
25434328 - Eur J Surg Oncol. 2015 Feb;41(2):228-35
18048884 - Integr Cancer Ther. 2007 Dec;6(4):365-72
17980029 - Breast Cancer Res. 2007;9(6):R76
20919930 - Antioxid Redox Signal. 2011 Aug 1;15(3):781-94
18406051 - Cancer Lett. 2008 Jul 18;266(1):37-52
24789097 - Int J Oncol. 2014 Jul;45(1):219-26
9497358 - J Biol Chem. 1998 Mar 13;273(11):6303-11
19098005 - J Biol Chem. 2009 Mar 6;284(10):6520-9
17927496 - Nutr Cancer. 2007;59(1):8-13
18372105 - Cancer Lett. 2008 Jul 18;266(1):30-6
18184874 - Am J Physiol Cell Physiol. 2008 Mar;294(3):C842-55
21859152 - J Proteome Res. 2011 Nov 4;10(11):4935-47
12530083 - Anticancer Res. 2002 Nov-Dec;22(6A):3331-5
19185987 - Cancer Lett. 2009 Sep 18;282(2):125-36
11233141 - Antioxid Redox Signal. 1999 Winter;1(4):385-402
19929132 - Physiol Res. 2010;59(4):459-69
11857495 - J Pathol. 2002 Mar;196(3):316-23
21863242 - Acta Neuropathol. 2011 Oct;122(4):495-510
16516038 - J Urol. 2006 Apr;175(4):1512-6
24316730 - Int J Oncol. 2014 Feb;44(2):548-56
19424615 - Oncol Rep. 2009 Jun;21(6):1391-6
17616437 - Curr Opin Pharmacol. 2007 Aug;7(4):375-80
22215146 - J Cancer Res Clin Oncol. 2012 Apr;138(4):621-6
26170166 - Cancer Lett. 2015 Oct 1;366(2):150-9
23227829 - Brain Pathol. 2013 Jul;23(4):413-25
References_xml – volume: 11
  start-page: 2452
  year: 2012
  ident: key20180107152254_b104-mco-0-0-1129
  article-title: Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro
  publication-title: J Proteome Res
  doi: 10.1021/pr201172n
– volume: 275
  start-page: 18801
  year: 2000
  ident: key20180107152254_b11-mco-0-0-1129
  article-title: The AhpC and AhpD antioxidant defense system of Mycobacterium tuberculosis
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M001001200
– volume: 67
  start-page: 546
  year: 2007
  ident: key20180107152254_b52-mco-0-0-1129
  article-title: Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: Implication to tumor biology
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-2401
– volume: 19
  start-page: 1047
  year: 2009
  ident: key20180107152254_b118-mco-0-0-1129
  article-title: DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma
  publication-title: Int J Gynecol Cancer
  doi: 10.1111/IGC.0b013e3181ad0f0d
– volume: 249
  start-page: 52
  year: 1997
  ident: key20180107152254_b95-mco-0-0-1129
  article-title: SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria
  publication-title: Eur J Biochem
  doi: 10.1111/j.1432-1033.1997.t01-1-00052.x
– volume: 21
  start-page: 1129
  year: 2001
  ident: key20180107152254_b156-mco-0-0-1129
  article-title: Increased expression of peroxiredoxin II confers resistance to cisplatin
  publication-title: Anticancer Res
– volume: 6
  start-page: 365
  year: 2007
  ident: key20180107152254_b38-mco-0-0-1129
  article-title: Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma
  publication-title: Integr Cancer Ther
  doi: 10.1177/1534735407309760
– volume: 23
  start-page: 413
  year: 2013
  ident: key20180107152254_b99-mco-0-0-1129
  article-title: MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3)
  publication-title: Brain Pathol
  doi: 10.1111/bpa.12014
– volume: 421
  start-page: 33
  year: 2012
  ident: key20180107152254_b71-mco-0-0-1129
  article-title: Human peroxiredoxin 1 modulates TGF-β1-induced epithelial-mesenchymal transition through its peroxidase activity
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2012.03.103
– volume: 2
  start-page: 801
  year: 2000
  ident: key20180107152254_b96-mco-0-0-1129
  article-title: The mitochondrial thioredoxin system
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2000.2.4-801
– volume: 11
  start-page: 64
  year: 2015
  ident: key20180107152254_b80-mco-0-0-1129
  article-title: Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.1695
– volume: 387
  start-page: 261
  year: 2014
  ident: key20180107152254_b94-mco-0-0-1129
  article-title: Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells' survival by protecting cells from oxidative stress
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1891-4
– volume: 29
  start-page: 21
  year: 2011
  ident: key20180107152254_b159-mco-0-0-1129
  article-title: Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells
  publication-title: Cancer Invest
  doi: 10.3109/07357907.2010.535056
– volume: 7
  start-page: 375
  year: 2007
  ident: key20180107152254_b166-mco-0-0-1129
  article-title: Are peroxiredoxins tumor suppressors?
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2007.04.007
– volume: 9
  start-page: 137
  year: 2011
  ident: key20180107152254_b107-mco-0-0-1129
  article-title: Peroxiredoxin 4: A multifunctional biomarker worthy of further exploration
  publication-title: BMC Med
  doi: 10.1186/1741-7015-9-137
– volume: 312
  start-page: 2806
  year: 2006
  ident: key20180107152254_b164-mco-0-0-1129
  article-title: Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2006.05.006
– volume: 91
  start-page: 7017
  year: 1994
  ident: key20180107152254_b15-mco-0-0-1129
  article-title: Cloning and sequencing of thiol-specific antioxidant from mammalian brain: Alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.91.15.7017
– volume: 38
  start-page: 1543
  year: 2005
  ident: key20180107152254_b21-mco-0-0-1129
  article-title: Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2005.02.026
– volume: 15
  start-page: 205
  year: 2005
  ident: key20180107152254_b128-mco-0-0-1129
  article-title: Peroxiredoxin 5 expression in the human thyroid gland
  publication-title: Thyroid
  doi: 10.1089/thy.2005.15.205
– volume: 53
  start-page: 24
  year: 2014
  ident: key20180107152254_b79-mco-0-0-1129
  article-title: Peroxiredoxin 2 nuclear levels are regulated by circadian clock synchronization in human keratinocytes
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2014.04.024
– volume: 16
  start-page: R79
  year: 2014
  ident: key20180107152254_b57-mco-0-0-1129
  article-title: Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3691
– volume: 19
  start-page: 1507
  year: 2013
  ident: key20180107152254_b97-mco-0-0-1129
  article-title: SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a/PGC-1α complex
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2012.4713
– volume: 17
  start-page: 553
  year: 2010
  ident: key20180107152254_b72-mco-0-0-1129
  article-title: Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells
  publication-title: Endocr Relat Cancer
  doi: 10.1677/ERC-09-0269
– volume: 51
  start-page: 794
  year: 1991
  ident: key20180107152254_b39-mco-0-0-1129
  article-title: Production of large amounts of hydrogen peroxide by human tumor cells
  publication-title: Cancer Res
– volume: 28
  start-page: 1505
  year: 2009
  ident: key20180107152254_b56-mco-0-0-1129
  article-title: Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity
  publication-title: EMBO J
  doi: 10.1038/emboj.2009.101
– volume: 300
  start-page: 650
  year: 2003
  ident: key20180107152254_b76-mco-0-0-1129
  article-title: Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling
  publication-title: Science
  doi: 10.1126/science.1080405
– volume: 1
  start-page: 385
  year: 1999
  ident: key20180107152254_b165-mco-0-0-1129
  article-title: From cytoprotection to tumor suppression: The multifactorial role of peroxiredoxins
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.1999.1.4-385
– volume: 263
  start-page: 4704
  year: 1988
  ident: key20180107152254_b14-mco-0-0-1129
  article-title: The isolation and purification of a specific ‘protector’ protein which inhibits enzyme inactivation by a thiol/Fe(III)/O2 mixed-function oxidation system
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)68840-4
– volume: 41
  start-page: 228
  year: 2015
  ident: key20180107152254_b66-mco-0-0-1129
  article-title: Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2014.11.037
– volume: 407
  start-page: 211
  year: 2000
  ident: key20180107152254_b10-mco-0-0-1129
  article-title: Peroxynitrite reductase activity of bacterial peroxiredoxins
  publication-title: Nature
  doi: 10.1038/35025109
– volume: 9
  start-page: 3418
  year: 2003
  ident: key20180107152254_b103-mco-0-0-1129
  article-title: Peroxiredoxins in breast carcinoma
  publication-title: Clin Cancer Res
– volume: 44
  start-page: 41
  year: 2007
  ident: key20180107152254_b29-mco-0-0-1129
  article-title: Structural survey of the peroxiredoxins
  publication-title: Subcell Biochem
  doi: 10.1007/978-1-4020-6051-9_3
– volume: 2000
  start-page: pe1
  year: 2000
  ident: key20180107152254_b6-mco-0-0-1129
  article-title: Hydrogen peroxide: A key messenger that modulates protein phosphorylation through cysteine oxidation
  publication-title: Sci STKE
  doi: 10.1126/stke.2000.53.pe1
– volume: 80
  start-page: 183
  year: 2015
  ident: key20180107152254_b12-mco-0-0-1129
  article-title: A primer on peroxiredoxin biochemistry
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2014.10.009
– volume: 10
  start-page: e0144851
  year: 2015
  ident: key20180107152254_b136-mco-0-0-1129
  article-title: The expression of porcine Prdx6 gene is up-regulated by C/EBPβ and CREB
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0144851
– volume: 45
  start-page: 219
  year: 2014
  ident: key20180107152254_b161-mco-0-0-1129
  article-title: Peroxiredoxin proteins protect MCF-7 breast cancer cells from doxorubicin-induced toxicity
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2014.2398
– volume: 32
  start-page: 724
  year: 2013
  ident: key20180107152254_b93-mco-0-0-1129
  article-title: Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs
  publication-title: Oncogene
  doi: 10.1038/onc.2012.93
– volume: 39
  start-page: 44
  year: 2007
  ident: key20180107152254_b1-mco-0-0-1129
  article-title: Free radicals and antioxidants in normal physiological functions and human disease
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2006.07.001
– volume: 284
  start-page: 22758
  year: 2009
  ident: key20180107152254_b134-mco-0-0-1129
  article-title: Loss of NF-kappaB control and repression of Prdx6 gene transcription by reactive oxygen species-driven SMAD3-mediated transforming growth factor beta signaling
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.016071
– volume: 175
  start-page: 1512
  year: 2006
  ident: key20180107152254_b61-mco-0-0-1129
  article-title: Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer
  publication-title: J Urol
  doi: 10.1016/S0022-5347(05)00659-2
– volume: 15
  start-page: 831
  year: 2011
  ident: key20180107152254_b130-mco-0-0-1129
  article-title: Peroxiredoxin 6: A bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3412
– volume: 15
  start-page: 795
  year: 2011
  ident: key20180107152254_b19-mco-0-0-1129
  article-title: Structure-based insights into the catalytic power and conformational dexterity of peroxiredoxins
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3624
– volume: 1769
  start-page: 472
  year: 2007
  ident: key20180107152254_b123-mco-0-0-1129
  article-title: Human peroxiredoxin 5 gene organization, initial characterization of its promoter and identification of alternative forms of mRNA
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbaexp.2007.05.004
– volume: 4
  start-page: 445
  year: 2014
  ident: key20180107152254_b70-mco-0-0-1129
  article-title: Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy
  publication-title: Am J Cancer Res
– volume: 8
  start-page: 4072
  year: 2009
  ident: key20180107152254_b51-mco-0-0-1129
  article-title: Peroxiredoxin 1 and its role in cell signaling
  publication-title: Cell Cycle
  doi: 10.4161/cc.8.24.10242
– volume: 119
  start-page: 4499
  year: 2012
  ident: key20180107152254_b59-mco-0-0-1129
  article-title: Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/PTPRJ
  publication-title: Blood
  doi: 10.1182/blood-2011-02-336446
– volume: 44
  start-page: 1578
  year: 2008
  ident: key20180107152254_b82-mco-0-0-1129
  article-title: PTEN deletion leads to deregulation of antioxidants and increased oxidative damage in mouse embryonic fibroblasts
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2008.01.013
– volume: 115
  start-page: 611
  year: 2008
  ident: key20180107152254_b137-mco-0-0-1129
  article-title: Peroxiredoxin 6 in human brain: Molecular forms, cellular distribution, and association with Alzheimer's disease pathology
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-008-0373-3
– volume: 175
  start-page: 8424
  year: 2005
  ident: key20180107152254_b35-mco-0-0-1129
  article-title: Expression and activity of NOX5 in the circulating malignant B cells of hairy cell leukemia
  publication-title: J Immunol
  doi: 10.4049/jimmunol.175.12.8424
– volume: 99
  start-page: 1950
  year: 2008
  ident: key20180107152254_b126-mco-0-0-1129
  article-title: Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high-mobility group protein B1
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2008.00912.x
– volume: 270
  start-page: 28635
  year: 1995
  ident: key20180107152254_b7-mco-0-0-1129
  article-title: Thioredoxin-linked ‘thiol peroxidase’ from periplasmic space of Escherichia coli
  publication-title: J Biol Chem
  doi: 10.1074/jbc.270.48.28635
– volume: 100
  start-page: 1303
  year: 2009
  ident: key20180107152254_b88-mco-0-0-1129
  article-title: Differential tissue-specific protein markers of vaginal carcinoma
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604975
– volume: 66
  start-page: 6080
  year: 2006
  ident: key20180107152254_b84-mco-0-0-1129
  article-title: Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-0157
– volume: 32
  start-page: 873
  year: 2008
  ident: key20180107152254_b129-mco-0-0-1129
  article-title: Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13
  publication-title: World J Surg
  doi: 10.1007/s00268-008-9521-0
– volume: 7
  start-page: 1717
  year: 2016
  ident: key20180107152254_b92-mco-0-0-1129
  article-title: Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6435
– volume: 10
  start-page: 2863
  year: 2011
  ident: key20180107152254_b142-mco-0-0-1129
  article-title: Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma
  publication-title: J Proteome Res
  doi: 10.1021/pr200141c
– volume: 383
  start-page: 347
  year: 2002
  ident: key20180107152254_b26-mco-0-0-1129
  article-title: Peroxiredoxins
  publication-title: Biol Chem
  doi: 10.1515/BC.2002.040
– volume: 104
  start-page: 4886
  year: 2007
  ident: key20180107152254_b28-mco-0-0-1129
  article-title: Reduction of 1-Cys peroxiredoxins by ascorbate changes the thiol-specific antioxidant paradigm, revealing another function of vitamin C
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0700481104
– volume: 145
  start-page: 127
  year: 1999
  ident: key20180107152254_b74-mco-0-0-1129
  article-title: Peroxiredoxin I expression in human thyroid tumors
  publication-title: Cancer Lett
  doi: 10.1016/S0304-3835(99)00243-8
– volume: 138
  start-page: 621
  year: 2012
  ident: key20180107152254_b91-mco-0-0-1129
  article-title: Polymorphisms of peroxiredoxin 1, 2 and 6 are not associated with esophageal cancer
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-011-1119-5
– volume: 12
  start-page: 931
  year: 2013
  ident: key20180107152254_b153-mco-0-0-1129
  article-title: Modulation of oxidative stress as an anticancer strategy
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4002
– volume: 12
  start-page: 7163
  year: 2011
  ident: key20180107152254_b162-mco-0-0-1129
  article-title: Mitochondrial peroxiredoxin III is a potential target for cancer therapy
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms12107163
– volume: 311
  start-page: 751
  year: 2001
  ident: key20180107152254_b27-mco-0-0-1129
  article-title: Crystal structure of human peroxiredoxin 5, a novel type of mammalian peroxiredoxin at 1.5 A resolution
  publication-title: J Mol Biol
  doi: 10.1006/jmbi.2001.4853
– volume: 19
  start-page: 482
  year: 2013
  ident: key20180107152254_b58-mco-0-0-1129
  article-title: Prx I suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK/cyclin D1 pathway
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2011.4421
– volume: 137
  start-page: 1229
  year: 2011
  ident: key20180107152254_b144-mco-0-0-1129
  article-title: Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-011-0992-2
– volume: 274
  start-page: 5804
  year: 2007
  ident: key20180107152254_b125-mco-0-0-1129
  article-title: Mitochondrial targeting of human peroxiredoxin V protein and regulation of PRDX5 gene expression by nuclear transcription factors controlling biogenesis of mitochondria
  publication-title: FEBS J
  doi: 10.1111/j.1742-4658.2007.06103.x
– volume: 21
  start-page: 1391
  year: 2009
  ident: key20180107152254_b89-mco-0-0-1129
  article-title: Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis
  publication-title: Oncol Rep
– volume: 586
  start-page: 2451
  year: 2012
  ident: key20180107152254_b100-mco-0-0-1129
  article-title: MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer
  publication-title: FEBS Lett
  doi: 10.1016/j.febslet.2012.06.003
– volume: 294
  start-page: C842
  year: 2008
  ident: key20180107152254_b140-mco-0-0-1129
  article-title: TAT-mediated PRDX6 protein transduction protects against eye lens epithelial cell death and delays lens opacity
  publication-title: Am J Physiol Cell Physiol
  doi: 10.1152/ajpcell.00540.2007
– volume: 15
  start-page: 781
  year: 2011
  ident: key20180107152254_b81-mco-0-0-1129
  article-title: Multiple functions of peroxiredoxins: Peroxidases, sensors and regulators of the intracellular messenger H2O2, and protein chaperones
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3393
– volume: 71
  start-page: 755
  year: 2011
  ident: key20180107152254_b90-mco-0-0-1129
  article-title: Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4
  publication-title: Prostate
  doi: 10.1002/pros.21292
– volume: 65
  start-page: 319
  year: 2014
  ident: key20180107152254_b127-mco-0-0-1129
  article-title: Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas
  publication-title: Histopathology
  doi: 10.1111/his.12389
– volume: 6
  start-page: 73
  year: 2014
  ident: key20180107152254_b155-mco-0-0-1129
  article-title: The role of peroxiredoxin II in chemoresistance of breast cancer cells
  publication-title: Breast Cancer (Dove Med Press)
– volume: 280
  start-page: 3125
  year: 2005
  ident: key20180107152254_b167-mco-0-0-1129
  article-title: Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins
  publication-title: J Biol Chem
  doi: 10.1074/jbc.C400496200
– volume: 10
  start-page: 867
  year: 2014
  ident: key20180107152254_b86-mco-0-0-1129
  article-title: Overexpression of peroxiredoxin 2 inhibits TGF-β1-induced epithelial-mesenchymal transition and cell migration in colorectal cancer
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2014.2316
– volume: 1810
  start-page: 111
  year: 2011
  ident: key20180107152254_b20-mco-0-0-1129
  article-title: Human protein atlas of redox systems-what can be learnt?
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbagen.2010.07.004
– volume: 46
  start-page: 1661
  year: 2010
  ident: key20180107152254_b87-mco-0-0-1129
  article-title: Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2010.02.006
– volume: 2015
  start-page: 654594
  year: 2015
  ident: key20180107152254_b42-mco-0-0-1129
  article-title: Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and cancer progression
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2015/654594
– volume: 66
  start-page: 3663
  year: 2009
  ident: key20180107152254_b46-mco-0-0-1129
  article-title: Reactive oxygen species-dependent signaling regulates cancer
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-009-0099-y
– volume: 50
  start-page: 91
  year: 2012
  ident: key20180107152254_b112-mco-0-0-1129
  article-title: Novel roles of peroxiredoxins in inflammation, cancer and innate immunity
  publication-title: J Clin Biochem Nutr
  doi: 10.3164/jcbn.11-109
– volume: 153
  start-page: 878
  year: 2012
  ident: key20180107152254_b157-mco-0-0-1129
  article-title: Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation
  publication-title: Bull Exp Biol Med
  doi: 10.1007/s10517-012-1849-7
– volume: 92
  start-page: 90
  year: 2014
  ident: key20180107152254_b152-mco-0-0-1129
  article-title: Targeting antioxidants for cancer therapy
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2014.07.017
– volume: 11
  start-page: 262
  year: 2011
  ident: key20180107152254_b117-mco-0-0-1129
  article-title: Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-11-262
– volume: 9
  start-page: 451
  year: 2010
  ident: key20180107152254_b62-mco-0-0-1129
  article-title: Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma
  publication-title: J Proteome Res
  doi: 10.1021/pr900811x
– volume: 141
  start-page: 2071
  year: 2015
  ident: key20180107152254_b163-mco-0-0-1129
  article-title: The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-015-1916-3
– volume: 266
  start-page: 53
  year: 2008
  ident: key20180107152254_b40-mco-0-0-1129
  article-title: Reactive oxygen species in tumor metastasis
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2008.02.031
– volume: 14
  start-page: 2326
  year: 2008
  ident: key20180107152254_b60-mco-0-0-1129
  article-title: Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-4457
– volume: 2
  start-page: 767
  year: 2014
  ident: key20180107152254_b119-mco-0-0-1129
  article-title: High expression of peroxiredoxin 4 affects the survival time of colorectal cancer patients, but is not an independent unfavorable prognostic factor
  publication-title: Mol Clin Oncol
  doi: 10.3892/mco.2014.317
– volume: 122
  start-page: 495
  year: 2011
  ident: key20180107152254_b68-mco-0-0-1129
  article-title: Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-011-0867-2
– volume: 6
  start-page: 4915
  year: 2000
  ident: key20180107152254_b158-mco-0-0-1129
  article-title: Antisense of human peroxiredoxin II enhances radiation-induced cell death
  publication-title: Clin Cancer Res
– volume: 108
  start-page: 7004
  year: 2011
  ident: key20180107152254_b120-mco-0-0-1129
  article-title: Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1013012108
– volume: 46
  start-page: 146
  year: 2009
  ident: key20180107152254_b133-mco-0-0-1129
  article-title: Oxidant stress stimulates expression of the human peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant response element
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2008.09.027
– volume: 26
  start-page: 185
  year: 2011
  ident: key20180107152254_b141-mco-0-0-1129
  article-title: Differential protein expression in primary breast cancer and matched axillary node metastasis
  publication-title: Oncol Rep
– volume: 30
  start-page: 5085
  year: 2010
  ident: key20180107152254_b109-mco-0-0-1129
  article-title: Investigation of peroxiredoxin IV as a calpain-regulated pathway in cancer
  publication-title: Anticancer Res
– volume: 149
  start-page: 443
  year: 2011
  ident: key20180107152254_b110-mco-0-0-1129
  article-title: Different consequences of reactions with hydrogen peroxide and t-butyl hydroperoxide in the hyperoxidative inactivation of rat peroxiredoxin-4
  publication-title: J Biochem
  doi: 10.1093/jb/mvq156
– volume: 26
  start-page: 304
  year: 2011
  ident: key20180107152254_b105-mco-0-0-1129
  article-title: Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer
  publication-title: Korean J Intern Med
  doi: 10.3904/kjim.2011.26.3.304
– volume: 51
  start-page: 7638
  year: 2012
  ident: key20180107152254_b18-mco-0-0-1129
  article-title: Mapping the active site helix-to-strand conversion of CxxxxC peroxiredoxin Q enzymes
  publication-title: Biochemistry
  doi: 10.1021/bi301017s
– volume: 20
  start-page: 3677
  year: 2013
  ident: key20180107152254_b154-mco-0-0-1129
  article-title: Reactive oxygen species in cancer biology and anticancer therapy
  publication-title: Curr Med Chem
  doi: 10.2174/0929867311320999165
– volume: 196
  start-page: 316
  year: 2002
  ident: key20180107152254_b67-mco-0-0-1129
  article-title: Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma
  publication-title: J Pathol
  doi: 10.1002/path.1042
– volume: 366
  start-page: 150
  year: 2015
  ident: key20180107152254_b113-mco-0-0-1129
  article-title: The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer development
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2015.07.002
– volume: 275
  start-page: 20346
  year: 2000
  ident: key20180107152254_b22-mco-0-0-1129
  article-title: Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M001943200
– volume: 469
  start-page: 498
  year: 2011
  ident: key20180107152254_b77-mco-0-0-1129
  article-title: Circadian clocks in human red blood cells
  publication-title: Nature
  doi: 10.1038/nature09702
– volume: 19
  start-page: C7
  year: 2012
  ident: key20180107152254_b3-mco-0-0-1129
  article-title: Oxidative stress: A new risk factor for thyroid cancer
  publication-title: Endocr Relat Cancer
  doi: 10.1530/ERC-11-0360
– volume: 6
  start-page: e16340
  year: 2011
  ident: key20180107152254_b121-mco-0-0-1129
  article-title: The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0016340
– volume: 9
  start-page: R76
  year: 2007
  ident: key20180107152254_b147-mco-0-0-1129
  article-title: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr1789
– volume: 79
  start-page: 947
  year: 2011
  ident: key20180107152254_b17-mco-0-0-1129
  article-title: Analysis of the peroxiredoxin family: Using active-site structure and sequence information for global classification and residue analysis
  publication-title: Proteins
  doi: 10.1002/prot.22936
– volume: 59
  start-page: 8
  year: 2007
  ident: key20180107152254_b36-mco-0-0-1129
  article-title: Oxidant stress and B vitamins status in patients with non-small cell lung cancer
  publication-title: Nutr Cancer
  doi: 10.1080/01635580701365043
– volume: 1
  start-page: 228
  year: 2013
  ident: key20180107152254_b106-mco-0-0-1129
  article-title: Peroxiredoxin 3 is a novel marker for cell proliferation in cervical cancer
  publication-title: Biomed Rep
  doi: 10.3892/br.2012.43
– volume: 9
  start-page: 825
  year: 2010
  ident: key20180107152254_b150-mco-0-0-1129
  article-title: Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-09-0904
– volume: 83
  start-page: 373
  year: 2015
  ident: key20180107152254_b24-mco-0-0-1129
  article-title: Physiological and pathological views of peroxiredoxin 4
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2015.01.025
– volume: 273
  start-page: 6303
  year: 1998
  ident: key20180107152254_b23-mco-0-0-1129
  article-title: Characterization of a mammalian peroxiredoxin that contains one conserved cysteine
  publication-title: J Biol Chem
  doi: 10.1074/jbc.273.11.6303
– volume: 7
  start-page: 123
  year: 2002
  ident: key20180107152254_b32-mco-0-0-1129
  article-title: Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein
  publication-title: Redox Rep
  doi: 10.1179/135100002125000352
– volume: 52
  start-page: 35
  year: 2001
  ident: key20180107152254_b25-mco-0-0-1129
  article-title: Peroxiredoxin, a novel family of peroxidases
  publication-title: IUBMB Life
  doi: 10.1080/15216540252774748
– volume: 69
  start-page: 1739
  year: 2009
  ident: key20180107152254_b115-mco-0-0-1129
  article-title: Conserved gene expression programs integrate mammalian prostate development and tumorigenesis
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-6817
– volume: 20
  start-page: 391
  year: 2014
  ident: key20180107152254_b132-mco-0-0-1129
  article-title: Keratinocyte growth factor and glucocorticoid induction of human peroxiredoxin 6 gene expression occur by independent mechanisms that are synergistic
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2012.4634
– volume: 44
  start-page: 317
  year: 2007
  ident: key20180107152254_b143-mco-0-0-1129
  article-title: Peroxiredoxins in the lung with emphasis on peroxiredoxin VI
  publication-title: Subcell Biochem
  doi: 10.1007/978-1-4020-6051-9_15
– volume: 378
  start-page: 827
  year: 1997
  ident: key20180107152254_b9-mco-0-0-1129
  article-title: A Unique cascade of oxidoreductases catalyses trypanothione-mediated peroxide metabolism in Crithidia fasciculata
  publication-title: Biol Chem
  doi: 10.1515/bchm.1997.378.8.827
– volume: 163
  start-page: 1
  year: 2016
  ident: key20180107152254_b48-mco-0-0-1129
  article-title: Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2016.03.018
– volume: 127
  start-page: 493
  year: 2000
  ident: key20180107152254_b108-mco-0-0-1129
  article-title: Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions
  publication-title: J Biochem
  doi: 10.1093/oxfordjournals.jbchem.a022632
– volume: 583
  start-page: 1809
  year: 2009
  ident: key20180107152254_b31-mco-0-0-1129
  article-title: The oligomeric conformation of peroxiredoxins links redox state to function
  publication-title: FEBS Lett
  doi: 10.1016/j.febslet.2009.05.029
– volume: 41
  start-page: 5493
  year: 2002
  ident: key20180107152254_b30-mco-0-0-1129
  article-title: Dimers to Doughnuts: Redox-sensitive oligomerization of 2-cysteine peroxiredoxins
  publication-title: Biochemistry
  doi: 10.1021/bi012173m
– volume: 266
  start-page: 30
  year: 2008
  ident: key20180107152254_b41-mco-0-0-1129
  article-title: Mechanisms of ROS modulated cell survival during carcinogenesis
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2008.02.029
– volume: 97
  start-page: 55
  year: 2015
  ident: key20180107152254_b33-mco-0-0-1129
  article-title: The role of antioxidants in the chemistry of oxidative stress: A review
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2015.04.040
– volume: 9
  start-page: e105529
  year: 2014
  ident: key20180107152254_b111-mco-0-0-1129
  article-title: A novel reaction of peroxiredoxin 4 towards substrates in oxidative protein folding
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0105529
– volume: 68
  start-page: 552
  year: 2015
  ident: key20180107152254_b146-mco-0-0-1129
  article-title: High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of international prognostic index
  publication-title: J Clin Pathol
  doi: 10.1136/jclinpath-2014-202771
– volume: 21
  start-page: 10840
  year: 2015
  ident: key20180107152254_b65-mco-0-0-1129
  article-title: Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v21.i38.10840
– volume: 16
  start-page: 123
  year: 2011
  ident: key20180107152254_b49-mco-0-0-1129
  article-title: Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
  publication-title: Genes Cells
  doi: 10.1111/j.1365-2443.2010.01473.x
– volume: 5
  start-page: 400
  year: 1998
  ident: key20180107152254_b131-mco-0-0-1129
  article-title: Crystal structure of a novel human peroxidase enzyme at 2.0 A resolution
  publication-title: Nat Struct Biol
  doi: 10.1038/nsb0598-400
– volume: 2014
  start-page: 209845
  year: 2014
  ident: key20180107152254_b50-mco-0-0-1129
  article-title: A paradoxical chemoresistance and tumor suppressive role of antioxidant in solid cancer cells: A strange case of Dr. Jekyll and Mr. Hyde
  publication-title: Biomed Res Int
  doi: 10.1155/2014/209845
– volume: 7
  start-page: e50394
  year: 2012
  ident: key20180107152254_b69-mco-0-0-1129
  article-title: Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0050394
– volume: 7
  start-page: 125
  year: 2007
  ident: key20180107152254_b53-mco-0-0-1129
  article-title: Differential regulation of abundance and deadenylation of maternal transcripts during bovine oocyte maturation in vitro and in vivo
  publication-title: BMC Dev Biol
  doi: 10.1186/1471-213X-7-125
– volume: 144
  start-page: 646
  year: 2011
  ident: key20180107152254_b45-mco-0-0-1129
  article-title: Hallmarks of cancer: The next generation
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 2
  start-page: e234
  year: 2011
  ident: key20180107152254_b135-mco-0-0-1129
  article-title: Specificity protein, Sp1-mediated increased expression of Prdx6 as a curcumin-induced antioxidant defense in lens epithelial cells against oxidative stress
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2011.121
– volume: 82
  start-page: 47
  year: 2002
  ident: key20180107152254_b4-mco-0-0-1129
  article-title: Free radicals in the physiological control of cell function
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00018.2001
– volume: 8
  start-page: 193
  year: 2009
  ident: key20180107152254_b114-mco-0-0-1129
  article-title: Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue
  publication-title: Hepatobiliary Pancreat Dis Int
– volume: 8
  start-page: 9863
  year: 2015
  ident: key20180107152254_b64-mco-0-0-1129
  article-title: Overexpression of Prdx1 in hilar cholangiocarcinoma: A predictor for recurrence and prognosis
  publication-title: Int J Clin Exp Pathol
– volume: 8
  start-page: 722
  year: 2007
  ident: key20180107152254_b5-mco-0-0-1129
  article-title: Hydrogen peroxide: A metabolic by-product or a common mediator of ageing signals?
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2240
– volume: 485
  start-page: 459
  year: 2012
  ident: key20180107152254_b16-mco-0-0-1129
  article-title: Peroxiredoxins are conserved markers of circadian rhythms
  publication-title: Nature
  doi: 10.1038/nature11088
– volume: 47
  start-page: e165
  year: 2015
  ident: key20180107152254_b160-mco-0-0-1129
  article-title: An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib
  publication-title: Exp Mol Med
  doi: 10.1038/emm.2015.24
– volume: 588
  start-page: 3390
  year: 2014
  ident: key20180107152254_b101-mco-0-0-1129
  article-title: Hypoxia inducible factor-1α suppresses Peroxiredoxin 3 expression to promote proliferation of CCRCC cells
  publication-title: FEBS Lett
  doi: 10.1016/j.febslet.2014.07.030
– volume: 35
  start-page: 6465
  year: 2015
  ident: key20180107152254_b148-mco-0-0-1129
  article-title: Increased peroxiredoxin 6 expression predicts biochemical recurrence in prostate cancer patients after radical prostatectomy
  publication-title: Anticancer Res
– volume: 310
  start-page: 154
  year: 2007
  ident: key20180107152254_b83-mco-0-0-1129
  article-title: Hand transcription factors cooperatively regulate development of the distal midline mesenchyme
  publication-title: Dev Biol
  doi: 10.1016/j.ydbio.2007.07.036
– volume: 2010
  start-page: 214074
  year: 2010
  ident: key20180107152254_b34-mco-0-0-1129
  article-title: Cellular stress responses: Cell survival and cell death
  publication-title: Int J Cell Biol
  doi: 10.1155/2010/214074
– volume: 22
  start-page: 3331
  year: 2002
  ident: key20180107152254_b102-mco-0-0-1129
  article-title: Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas
  publication-title: Anticancer Res
– volume: 10
  start-page: 4935
  year: 2011
  ident: key20180107152254_b116-mco-0-0-1129
  article-title: Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology
  publication-title: J Proteome Res
  doi: 10.1021/pr200311p
– volume: 52
  start-page: 422
  year: 2015
  ident: key20180107152254_b138-mco-0-0-1129
  article-title: PRDX6 exacerbates dopaminergic neurodegeneration in a MPTP mouse model of Parkinson's disease
  publication-title: Mol Neurobiol
  doi: 10.1007/s12035-014-8885-4
– volume: 44
  start-page: 548
  year: 2014
  ident: key20180107152254_b75-mco-0-0-1129
  article-title: PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2013.2208
– volume: 24
  start-page: 8038
  year: 2005
  ident: key20180107152254_b55-mco-0-0-1129
  article-title: Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1208821
– volume: 5
  start-page: 127
  year: 2009
  ident: key20180107152254_b145-mco-0-0-1129
  article-title: Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response
  publication-title: Cancer Biomark
  doi: 10.3233/CBM-2009-0604
– volume: 2012
  start-page: 762825
  year: 2012
  ident: key20180107152254_b44-mco-0-0-1129
  article-title: Oxidative stress, tumor microenvironment, and metabolic reprogramming: A diabolic liaison
  publication-title: Int J Cell Biol
  doi: 10.1155/2012/762825
– volume: 19
  start-page: 173
  year: 2014
  ident: key20180107152254_b139-mco-0-0-1129
  article-title: Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease
  publication-title: Cell Stress Chaperones
  doi: 10.1007/s12192-013-0442-y
– volume: 166
  start-page: 657
  year: 2012
  ident: key20180107152254_b149-mco-0-0-1129
  article-title: Proteomic profiling of follicular and papillary thyroid tumors
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-11-0856
– volume: 111
  start-page: 12043
  year: 2014
  ident: key20180107152254_b78-mco-0-0-1129
  article-title: Circadian rhythm of hyperoxidized peroxiredoxin II is determined by hemoglobin autoxidation and the 20S proteasome in red blood cells
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1401100111
– volume: 282
  start-page: 125
  year: 2009
  ident: key20180107152254_b37-mco-0-0-1129
  article-title: Oxidative stress in prostate cancer
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2008.12.011
– volume: 284
  start-page: 6520
  year: 2009
  ident: key20180107152254_b124-mco-0-0-1129
  article-title: Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M807564200
– volume: 233
  start-page: 848
  year: 1997
  ident: key20180107152254_b8-mco-0-0-1129
  article-title: Bacterial scavengase p20 is structurally and functionally related to peroxiredoxins
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.1997.6564
– volume: 30
  start-page: 1106
  year: 2009
  ident: key20180107152254_b73-mco-0-0-1129
  article-title: Peroxiredoxin I contributes to TRAIL resistance through suppression of redox-sensitive caspase activation in human hepatoma cells
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgp104
– volume: 11
  start-page: 85
  year: 2011
  ident: key20180107152254_b47-mco-0-0-1129
  article-title: Regulation of cancer cell metabolism
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2981
– volume: 22
  start-page: 817
  year: 2013
  ident: key20180107152254_b151-mco-0-0-1129
  article-title: Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients-potential differential effects by radiotherapy?
  publication-title: Breast
  doi: 10.1016/j.breast.2013.02.008
– volume: 73
  start-page: 4744
  year: 2013
  ident: key20180107152254_b85-mco-0-0-1129
  article-title: Peroxiredoxin-2 represses melanoma metastasis by increasing E-Cadherin/β-Catenin complexes in adherens junctions
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-4226
– volume: 4
  start-page: 278
  year: 2008
  ident: key20180107152254_b13-mco-0-0-1129
  article-title: Reconciling the chemistry and biology of reactive oxygen species
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.85
– volume: 30
  start-page: 2297
  year: 2013
  ident: key20180107152254_b63-mco-0-0-1129
  article-title: Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma
  publication-title: Oncol Rep
  doi: 10.3892/or.2013.2714
– volume: 266
  start-page: 37
  year: 2008
  ident: key20180107152254_b43-mco-0-0-1129
  article-title: Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2008.02.044
– volume: 424
  start-page: 561
  year: 2003
  ident: key20180107152254_b54-mco-0-0-1129
  article-title: Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression
  publication-title: Nature
  doi: 10.1038/nature01819
– volume: 149
  start-page: 1006
  year: 2015
  ident: key20180107152254_b98-mco-0-0-1129
  article-title: FOXM1-Induced PRX3 regulates stemness and survival of colon cancer cells via maintenance of mitochondrial function
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.06.007
– volume: 15
  start-page: 817
  year: 2011
  ident: key20180107152254_b122-mco-0-0-1129
  article-title: Peroxiredoxin 5: Structure, mechanism, and function of the mammalian atypical 2-Cys peroxiredoxin
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3584
– volume: 59
  start-page: 459
  year: 2010
  ident: key20180107152254_b2-mco-0-0-1129
  article-title: Some current insights into oxidative stress
  publication-title: Physiol Res
  doi: 10.33549/physiolres.931844
– reference: 19369943 - EMBO J. 2009 May 20;28(10 ):1505-17
– reference: 17927496 - Nutr Cancer. 2007;59(1):8-13
– reference: 21031435 - Prostate. 2011 May 15;71(7):755-65
– reference: 9168946 - Biochem Biophys Res Commun. 1997 Apr 28;233(3):848-52
– reference: 9497358 - J Biol Chem. 1998 Mar 13;273(11):6303-11
– reference: 22666258 - Int J Cell Biol. 2012;2012:762825
– reference: 19016754 - Cancer Sci. 2008 Oct;99(10):1950-9
– reference: 22475482 - Biochem Biophys Res Commun. 2012 Apr 27;421(1):33-7
– reference: 21287625 - Proteins. 2011 Mar;79(3):947-64
– reference: 11857495 - J Pathol. 2002 Mar;196(3):316-23
– reference: 22710126 - FEBS Lett. 2012 Jul 30;586(16):2451-8
– reference: 11795591 - IUBMB Life. 2001 Jul;52(1-2):35-41
– reference: 1846317 - Cancer Res. 1991 Feb 1;51(3):794-8
– reference: 20182529 - Int J Cell Biol. 2010;2010:214074
– reference: 25402766 - Nat Chem Biol. 2015 Jan;11(1):64-70
– reference: 17616437 - Curr Opin Pharmacol. 2007 Aug;7(4):375-80
– reference: 20647035 - Biochim Biophys Acta. 2011 Jan;1810(1):111-38
– reference: 21376230 - Cell. 2011 Mar 4;144(5):646-74
– reference: 22438257 - Blood. 2012 May 10;119(19):4499-511
– reference: 25011585 - Breast Cancer Res. 2014 Jul 10;16(4):R79
– reference: 22072940 - Int J Mol Sci. 2011;12(10):7163-85
– reference: 8041738 - Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7017-21
– reference: 16516038 - J Urol. 2006 Apr;175(4):1512-6
– reference: 25137134 - PLoS One. 2014 Aug 19;9(8):e105529
– reference: 19553668 - J Biol Chem. 2009 Aug 21;284(34):22758-72
– reference: 25054044 - Mol Clin Oncol. 2014 Sep;2(5):767-772
– reference: 22215146 - J Cancer Res Clin Oncol. 2012 Apr;138(4):621-6
– reference: 19424615 - Oncol Rep. 2009 Jun;21(6):1391-6
– reference: 25232487 - Am J Cancer Res. 2014 Sep 06;4(5):445-60
– reference: 24920174 - Mol Med Rep. 2014 Aug;10(2):867-73
– reference: 12891360 - Nature. 2003 Jul 31;424(6948):561-5
– reference: 16170382 - Oncogene. 2005 Dec 1;24(54):8038-50
– reference: 19098005 - J Biol Chem. 2009 Mar 6;284(10):6520-9
– reference: 22196027 - BMC Med. 2011 Dec 23;9:137
– reference: 22424448 - J Proteome Res. 2012 Apr 6;11(4):2452-66
– reference: 21859152 - J Proteome Res. 2011 Nov 4;10(11):4935-47
– reference: 22622569 - Nature. 2012 May 16;485(7399):459-64
– reference: 22448089 - J Clin Biochem Nutr. 2012 Mar;50(2):91-105
– reference: 22016591 - Korean J Intern Med. 2011 Sep;26(3):304-13
– reference: 17700625 - Nat Rev Mol Cell Biol. 2007 Sep;8(9):722-8
– reference: 26021759 - Exp Mol Med. 2015 May 29;47:e165
– reference: 17234762 - Cancer Res. 2007 Jan 15;67(2):546-54
– reference: 17360337 - Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4886-91
– reference: 18413821 - Clin Cancer Res. 2008 Apr 15;14(8):2326-33
– reference: 25935550 - J Clin Pathol. 2015 Jul;68(7):552-6
– reference: 18084889 - Subcell Biochem. 2007;44:41-60
– reference: 18084901 - Subcell Biochem. 2007;44:317-44
– reference: 12960131 - Clin Cancer Res. 2003 Aug 15;9(9):3418-24
– reference: 24234423 - Mol Cell Biochem. 2014 Feb;387(1-2):261-70
– reference: 18275859 - Free Radic Biol Med. 2008 Apr 15;44(8):1578-91
– reference: 22143496 - Endocr Relat Cancer. 2012 Jan 09;19(1):C7-11
– reference: 20977338 - Antioxid Redox Signal. 2011 Aug 1;15(3):817-29
– reference: 24698430 - Histopathology. 2014 Sep;65(3):319-27
– reference: 25434328 - Eur J Surg Oncol. 2015 Feb;41(2):228-35
– reference: 23489758 - Breast. 2013 Oct;22(5):817-23
– reference: 23862622 - Curr Med Chem. 2013;20(30):3677-92
– reference: 26478675 - World J Gastroenterol. 2015 Oct 14;21(38):10840-52
– reference: 10751410 - J Biol Chem. 2000 Jul 7;275(27):20346-54
– reference: 11752613 - Sci STKE. 2000 Oct 10;2000(53):pe1
– reference: 7499381 - J Biol Chem. 1995 Dec 1;270(48):28635-41
– reference: 16339585 - J Immunol. 2005 Dec 15;175(12):8424-30
– reference: 19902980 - J Proteome Res. 2010 Jan;9(1):451-7
– reference: 19923889 - Cell Cycle. 2009 Dec 15;8(24):4072-8
– reference: 18973804 - Free Radic Biol Med. 2009 Jan 15;46(2):146-53
– reference: 23227829 - Brain Pathol. 2013 Jul;23(4):413-25
– reference: 15917183 - Free Radic Biol Med. 2005 Jun 15;38(12):1543-52
– reference: 20354123 - Mol Cancer Ther. 2010 Apr;9(4):825-32
– reference: 23186333 - Antioxid Redox Signal. 2013 Aug 10;19(5):482-96
– reference: 11969410 - Biochemistry. 2002 Apr 30;41(17):5493-504
– reference: 20206498 - Eur J Cancer. 2010 Jun;46(9):1661-7
– reference: 19185987 - Cancer Lett. 2009 Sep 18;282(2):125-36
– reference: 12714747 - Science. 2003 Apr 25;300(5619):650-3
– reference: 21251164 - Genes Cells. 2011 Feb;16(2):123-40
– reference: 11233141 - Antioxid Redox Signal. 1999 Winter;1(4):385-402
– reference: 25078786 - Biochem Pharmacol. 2014 Nov 1;92(1):90-101
– reference: 10731722 - J Biochem. 2000 Mar;127(3):493-501
– reference: 21503584 - Oncol Rep. 2011 Jul;26(1):185-91
– reference: 24648924 - Biomed Rep. 2013 Mar;1(2):228-230
– reference: 26078812 - Oxid Med Cell Longev. 2015;2015:654594
– reference: 10766746 - J Biol Chem. 2000 Jun 23;275(25):18801-9
– reference: 22275472 - Eur J Endocrinol. 2012 Apr;166(4):657-67
– reference: 20919932 - Antioxid Redox Signal. 2011 Aug 1;15(3):831-44
– reference: 25193021 - Mol Neurobiol. 2015 Aug;52(1):422-31
– reference: 16778180 - Cancer Res. 2006 Jun 15;66(12):6080-6
– reference: 19223557 - Cancer Res. 2009 Mar 1;69(5):1739-47
– reference: 12189041 - Redox Rep. 2002;7(3):123-30
– reference: 21166495 - Cancer Invest. 2011 Jan;29(1):21-8
– reference: 23749642 - Cancer Res. 2013 Aug 1;73(15):4744-57
– reference: 11001062 - Nature. 2000 Sep 14;407(6801):211-5
– reference: 19357035 - Hepatobiliary Pancreat Dis Int. 2009 Apr;8(2):193-200
– reference: 25092340 - Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12043-8
– reference: 12530083 - Anticancer Res. 2002 Nov-Dec;22(6A):3331-5
– reference: 24316730 - Int J Oncol. 2014 Feb;44(2):548-56
– reference: 17628720 - Biochim Biophys Acta. 2007 Jul-Aug;1769(7-8):472-83
– reference: 26636537 - Oncotarget. 2016 Jan 12;7(2):1717-31
– reference: 26659441 - PLoS One. 2015 Dec 14;10(12):e0144851
– reference: 11213484 - Antioxid Redox Signal. 2000 Winter;2(4):801-10
– reference: 9363753 - Eur J Biochem. 1997 Oct 1;249(1):52-60
– reference: 19367286 - Br J Cancer. 2009 Apr 21;100(8):1303-14
– reference: 18048884 - Integr Cancer Ther. 2007 Dec;6(4):365-72
– reference: 21283726 - PLoS One. 2011 Jan 20;6(1):e16340
– reference: 19629388 - Cell Mol Life Sci. 2009 Dec;66(23):3663-73
– reference: 18184874 - Am J Physiol Cell Physiol. 2008 Mar;294(3):C842-55
– reference: 21517111 - J Proteome Res. 2011 Jun 3;10(6):2863-72
– reference: 25875582 - J Cancer Res Clin Oncol. 2015 Dec;141(12):2071-7
– reference: 23461683 - Antioxid Redox Signal. 2013 Nov 1;19(13):1507-21
– reference: 23185615 - PLoS One. 2012;7(11):e50394
– reference: 2895105 - J Biol Chem. 1988 Apr 5;263(10):4704-11
– reference: 21693047 - BMC Cancer. 2011 Jun 21;11:262
– reference: 21258394 - Nat Rev Cancer. 2011 Feb;11(2):85-95
– reference: 19406930 - Carcinogenesis. 2009 Jul;30(7):1106-14
– reference: 24814289 - Int J Biochem Cell Biol. 2014 Aug;53:24-34
– reference: 10530780 - Cancer Lett. 1999 Oct 18;145(1-2):127-32
– reference: 20969484 - Antioxid Redox Signal. 2011 Aug 1;15(3):795-815
– reference: 18406051 - Cancer Lett. 2008 Jul 18;266(1):37-52
– reference: 15590625 - J Biol Chem. 2005 Feb 4;280(5):3125-8
– reference: 21187494 - Anticancer Res. 2010 Dec;30(12):5085-9
– reference: 19820366 - Int J Gynecol Cancer. 2009 Aug;19(6):1047-51
– reference: 17988387 - BMC Dev Biol. 2007 Nov 07;7:125
– reference: 18362051 - Cancer Lett. 2008 Jul 18;266(1):53-9
– reference: 19407367 - Cancer Biomark. 2009;5(3):127-35
– reference: 25656995 - Free Radic Biol Med. 2015 Jun;83:373-9
– reference: 15785239 - Thyroid. 2005 Mar;15(3):205-9
– reference: 26091938 - Gastroenterology. 2015 Oct;149(4):1006-16.e9
– reference: 25452140 - Free Radic Biol Med. 2015 Mar;80:183-90
– reference: 18421291 - Nat Chem Biol. 2008 May;4(5):278-86
– reference: 21691750 - J Cancer Res Clin Oncol. 2011 Aug;137(8):1229-38
– reference: 24789097 - Int J Oncol. 2014 Jul;45(1):219-26
– reference: 22113199 - Cell Death Dis. 2011 Nov 24;2:e234
– reference: 18372105 - Cancer Lett. 2008 Jul 18;266(1):30-6
– reference: 23815338 - Antioxid Redox Signal. 2014 Jan 20;20(3):391-402
– reference: 9377478 - Biol Chem. 1997 Aug;378(8):827-36
– reference: 24976757 - Breast Cancer (Dove Med Press). 2014 May 23;6:73-80
– reference: 16978905 - Int J Biochem Cell Biol. 2007;39(1):44-84
– reference: 21270888 - Nature. 2011 Jan 27;469(7331):498-503
– reference: 24009050 - Oncol Rep. 2013 Nov;30(5):2297-303
– reference: 22430214 - Oncogene. 2013 Feb 7;32(6):724-35
– reference: 24800215 - Biomed Res Int. 2014;2014:209845
– reference: 9587003 - Nat Struct Biol. 1998 May;5(5):400-6
– reference: 27130805 - Pharmacol Ther. 2016 Jul;163:1-23
– reference: 11518528 - J Mol Biol. 2001 Aug 24;311(4):751-9
– reference: 22928725 - Biochemistry. 2012 Sep 25;51(38):7638-50
– reference: 24287781 - Nat Rev Drug Discov. 2013 Dec;12(12):931-47
– reference: 26637857 - Anticancer Res. 2015 Dec;35(12):6465-70
– reference: 26617696 - Int J Clin Exp Pathol. 2015 Sep 01;8(9):9863-74
– reference: 18386021 - Acta Neuropathol. 2008 Jun;115(6):611-22
– reference: 16781710 - Exp Cell Res. 2006 Sep 10;312(15):2806-15
– reference: 11156252 - Clin Cancer Res. 2000 Dec;6(12):4915-20
– reference: 20919930 - Antioxid Redox Signal. 2011 Aug 1;15(3):781-94
– reference: 25942353 - Eur J Med Chem. 2015 Jun 5;97:55-74
– reference: 19464293 - FEBS Lett. 2009 Jun 18;583(12):1809-16
– reference: 12033427 - Biol Chem. 2002 Mar-Apr;383(3-4):347-64
– reference: 11773609 - Physiol Rev. 2002 Jan;82(1):47-95
– reference: 19929132 - Physiol Res. 2010;59(4):459-69
– reference: 25093297 - FEBS Lett. 2014 Sep 17;588(18):3390-4
– reference: 17980029 - Breast Cancer Res. 2007;9(6):R76
– reference: 18324346 - World J Surg. 2008 May;32(5):873-81
– reference: 21212070 - J Biochem. 2011 Apr;149(4):443-53
– reference: 17937766 - FEBS J. 2007 Nov;274(22):5804-14
– reference: 21863242 - Acta Neuropathol. 2011 Oct;122(4):495-510
– reference: 26170166 - Cancer Lett. 2015 Oct 1;366(2):150-9
– reference: 23801458 - Cell Stress Chaperones. 2014 Mar;19(2):173-81
– reference: 20410161 - Endocr Relat Cancer. 2010 Jun 03;17 (3):553-60
– reference: 23113308 - Bull Exp Biol Med. 2012 Oct;153(6):878-81
– reference: 11396151 - Anticancer Res. 2001 Mar-Apr;21(2A):1129-33
– reference: 17764670 - Dev Biol. 2007 Oct 1;310(1):154-68
– reference: 21487000 - Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7004-9
SSID ssj0000970259
ssib053393498
Score 2.424237
Snippet Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H O , organic...
Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 KDa) non-seleno peroxidases that catalyze the peroxide reduction of...
Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22–27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H2O2, organic...
Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H2O2, organic...
Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22–27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H 2 O 2 ,...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 139
SubjectTerms Antioxidants
Apoptosis
Bladder cancer
Breast cancer
Cancer
Care and treatment
Drug resistance
Enzymes
Esophageal cancer
Free radicals
Liver cancer
Lung cancer
Lymphoma
Mammals
Mesothelioma
Metabolites
Oncology
Organisms
Ovarian cancer
Oxidative stress
Pancreatic cancer
Peroxides
Phylogenetics
Prostate cancer
Reactive oxygen species
Review
Signal transduction
Thyroid gland
Tumors
Title The role of peroxiredoxins in cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/28357082
https://www.proquest.com/docview/1994977244
https://www.proquest.com/docview/1882497716
https://pubmed.ncbi.nlm.nih.gov/PMC5351761
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NT9wwEB1RuHCpilpo6IJSCcGFiMR27PUJUQRCPSCEQNqblfhDXanNLuwi7c9nJvGmpFI5e5I4MxO_GWf8BuBIqEpXkuctT2UmMKDIxkz4TNixdSwPmoe2QPZW3jyKn5NyEjfcFrGscr0mtgu1m1naIz8jDluMVRCNzudPGXWNor-rsYXGB9gqMBKh1g1q0sMpPlhzEdOJdmXWCiGeImKGgXGmRZl3tJuI2uzsj6XDgIWiUzV6AFP_LtZv0GpYSfkGmq4_wccYU6YXnRPswIZvPsMROkBKtYPpLKTEBr6aEjfoatos0mmTWrL28xd4vL56uLzJYkuEzIqCLTMeHCZ8TCuPaUgVaiGFL0onZZBcOl-X1rmK1457WQReh-BY7RF-uGeVqjznu7DZzBr_FVKldah94NYFK7ytdG5rjBZVyAOi-pglcLrWgLGRL5zaVvw2mDeQwgwqzJDCDCksgeNefN4RZfxP8ITUaegDwvvZKp4DwFkRFZW5EGg0McZINIHRQBId3w6H1wYx8cNbmL9uksD3fpiupGKyxs9eUAazChIqZAJ7nf36KRP9nMrp7dXAsr0A0XEPR5rpr5aWu-RloWSx__60vsE2qaIr_B7B5vL5xR9gXLOsD1vnPYStH1e3d_evtu_1hA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB4hemgvVSv6SEtLKlG4NCKxHXt9QBUqoKU8TiDtzU38ECu1WcouKvwpfiMzeZUgtTfOnkTOPDzfxOPPAOtCFbqQPK15KhOBgCIZMeETYUfWsTRoHuoG2RM5PhPfJ_lkCW67szDUVtmtifVC7WaW_pFvEYctYhXMRl8vfid0axTtrnZXaDRucehv_mDJNt8-2EX7fmZsf-_02zhpbxVIrMjYIuHBYc3EtPKI5ItQCil8ljspg-TS-TK3zhW8dNzLLPAyBMdKjys496xQhacfoLjkPxG0xYjxoyZ9-sYP1Vy05UudCbRCSEEInCEQT7TI04bmE1EC2_pl6fBhpugUjx6kxYfJ4V52HHZu3kuF-y_geYth453G6V7Ckq9WYB0dLqZexXgWYmIfv54SF-n1tJrH0yq25F2Xr-DsUZT1GparWeXfQqy0DqUP3LpghbeFTm2J6FSFNCCKGLEIvnQaMLblJ6drMn4arFNIYQYVZkhhhhQWwUYvftEQc_xLcJPUaShg8X22aM8d4KyI-srsCDSaGCHyjWB1IImBZofDnUFMG-hz89ctI_jUD9OT1LxW-dkVymAVQ0KZjOBNY79-ykR3p1L6ejWwbC9A9N_DkWp6XtOA5zzPlMze_X9aa_B0fHp8ZI4OTg7fwzNSS9N0vgrLi8sr_wEx1aL8WDtyDD8eO3LuAGrRMs4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LTxRBEK4QSIwXoxF1FHVIUC9Odqa7p3v7YAwRNyCGeJBkb-1MP-ImMAvsEuCv8euompeMCdw4d-2mpx5dX81UfwWwJVShC8nTmqcyEQgokjETPhF2bB1Lg-ahbpA9kLuH4sc0n67AdXcXhtoquzOxPqjd3NI78hFx2CJWwWw0Cm1bxK-dydeT04QmSNGX1m6cRuMi-_7qAsu3xZe9HbT1B8Ym339_203aCQOJFRlbJjw4rJ-YVh5RfRFKIYXPcidlkFw6X-bWuYKXjnuZBV6G4Fjp8TTnnhWq8PQyFI__NcWFoLERatqncnxozUVbytRZQSuEF4TGGYLyRIs8bSg_ETGw0bGli4iZohs9epAi_08UtzLlsIvzVlqcPIUnLZ6NtxsHfAYrvnoOW-h8MfUtxvMQExP55Yx4SS9n1SKeVbElTztbh8MHUdYLWK3mlX8FsdI6lD5w64IV3hY6tSUiVRXSgIhizCL43GnA2JarnEZmHBmsWUhhBhVmSGGGFBbBx178pCHpuEvwE6nTUPDi_9mivYOAuyIaLLMt0GhijCg4go2BJAadHS53BjFt0C_MPxeNYLNfpl9SI1vl5-cogxUNCWUygpeN_fotE_WdSunp1cCyvQBRgQ9XqtnfmhI853mmZPb6_m29h0cYM-bn3sH-G3hMWmn6zzdgdXl27t8ivFqW72o_juHPQwfODZY5NwE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+role+of+peroxiredoxins+in+cancer&rft.jtitle=Molecular+and+clinical+oncology&rft.au=Nicolussi%2C+Arianna&rft.au=D%27Inzeo%2C+Sonia&rft.au=Capalbo%2C+Carlo&rft.au=Giannini%2C+Giuseppe&rft.date=2017-02-01&rft.issn=2049-9450&rft.volume=6&rft.issue=2&rft.spage=139&rft_id=info:doi/10.3892%2Fmco.2017.1129&rft_id=info%3Apmid%2F28357082&rft.externalDocID=28357082
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2049-9450&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2049-9450&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2049-9450&client=summon